Catalog Advanced Search

Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Contains 1 Component(s) Recorded On: 12/08/2021

    Join Editors and Authors from the Assay Guidance Manual Special Issue and Collection in SLAS Discovery and SLAS Technology as they discuss their work and the implications it has to the field.

    Join Editors and Authors from the Assay Guidance Manual Special Issue and Collection in SLAS Discovery and SLAS Technology as they discuss their work and the implications it has to the field. 

    Introduction to the Assay Guidance Manual programand the scope of this Special Issue and Collection
    Sarine Markossian and G. Sitta Sittampalam, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)

    Complex tumor spheroids, a tissue mimicking tumor model, for drug discovery and precision medicine 
    Nathan P. Coussens, Frederick National Laboratory for Cancer Research

    Addressing compound reactivity and aggregation assay interferences: case studies of biochemical high-throughput screening campaigns benefiting from the National Institutes of Health Assay Guidance Manual guidelines 
    Jayme L. Dahlin, NCATS, NIH

    The Impact of Assay Design on Medicinal Chemistry: Case Studies
    Samarjit Patnaik, NCATS, NIH

    Busting Myths in Compound Handling Practices for Assay Developers
    Rosalia Gonzales, Pfizer Inc.

    Sarine Markossian

    National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)

    G. Sitta Sittampalam

    National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)

    Nathan Coussens

    Frederick National Laboratory for Cancer Research

    Jayme L. Dahlin, M.D., Ph.D.

    FASCP Preclinical Medical Director

    National Center for Advancing Translational Sciences (NCATS)

    Samarjit Patnaik

    National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)

    Rosalia Gonzales

    Pfizer Inc.

  • Contains 21 Component(s)

    These recordings address the successes and limitations of using 3D systems in discovery and applied research, while acknowledging the need for improvements to ensure widespread adoption.

    These recordings address the successes and limitations of using 3D systems in discovery and applied research, while acknowledging the need for improvements to ensure widespread adoption.

    Topics include:

    current and near-future enabling technologies,
    applications of such systems in high-throughput screening,
    advances in imaging and analysis of data generated
    and the expansion into novel model systems.

    Randy D. Blakely, Ph.D.

    Executive Director, FAU Brain Institute, Professor of Biomedical Science, Charles E. Schmidt College of Medicine

    Florida Atlantic University

    Joern Dengjel, Ph.D

    University of Friborg

    Hongjun Song, Ph.D.

    University of Pennsylvania

    James Hoying, Ph.D.

    Advanced Solutions Life Sciences

    Daniel Todd, Ph.D.

    Charles River Laboratories

    Joseph Kissil, Ph.D.

    Moffitt Cancer Center

    Kristin Bircsaka, Ph.D.

    MIMETAS

    Paul Johnston, Ph.D.

    University of Pittsburgh Dept. Pharmaceutical Sci.

    Dr. Johnston obtained a B.Sc. with Honors (2.1) (1978) and a Ph.D. (1983) in Biochemistry, from the University of East Anglia, Norwich, England. Postdoctoral positions at the University of North Carolina, Duke University, and the University of Texas Southwestern Howard Hughes Institute provided diverse experience in biochemistry, molecular biology, cell biology, immunology, protein purification and recombinant protein expression. Dr Johnston has twenty-nine years of drug discovery experience in the Pharmaceutical, Biotechnology, and Academic sectors. He is an innovator of cell based lead generation, and founding member of the Society for Biomolecular Imaging and Informatics. In 2005, he joined the University of Pittsburgh to design and build the Pittsburgh Molecular Library Screening Center where he led 21 HTS campaigns and the NCI 60 drug combination screen. In 2011, he established independent chemical biology laboratories to discover new drugs or drug combinations for prostate cancer, melanoma, and head and neck cancers.

    Paul Kenny, Ph.D.

    Mt. Sinai Icahn School of Medicine

    Nikolay Samusik, Ph.D.

    Genentech

    Sven Fengler, Ph.D.

    German Center for Neurodegenerative Diseases

    Andrew Aguirre, M.D., Ph.D.

    Harvard Medical School

    Carla Grandori, M.D., Ph.D.

    SEngine Precision Medicine

    James Hickman, Ph.D.

    University of Central Florida NanoScience Technology Center

    Pouria Rafsanjani Nejad

    The University of Akron

    David Tuveson, M.D., Ph.D.

    Cold Spring Harbor Laboratory

    Sarah Moss

    Linda Boekestijn

    Evan Cromwell

    Emma Ãkerlund

    Oksana Sirenko

  • Contains 17 Component(s)

    The SLAS 2021 Americas Sample Management Symposium welcomes all compound and sample management professionals – both in the lab and in leadership – to obtain fresh perspectives and share innovative solutions to challenges in these domains.

    Sample management is the bedrock of every phase of chemical and biological discovery. The past year has tested both academic and industrial programs and even in the best of times, there’s room for improvement in our processes. This year’s program will focus on best practices, lessons learned and new trends in sample management with an emphasis on the impact and potential of emerging technologies and applications of automation. We will also address the business of sample management as it pertains to mergers and acquisitions, the pros and cons of outsourcing and growing challenges in our supply chain. The SLAS 2021 Americas Sample Management Symposium welcomes all compound and sample management professionals – both in the lab and in leadership – to obtain fresh perspectives and share innovative solutions to challenges in these domains.

    Alison Keelen

    Scientist

    Bristol Myers Squibb

    Amanda Lembke

    Research Operations Senior Manager

    Amgen, Inc.

    Moana Simpson

    Manager, Compounds Australia

    Griffith University

    Ms Moana Simpson is the Manager of Compounds Australia, and has over 20 years’ experience in providing support for drug discovery research within Australia and the UK, both in academia and in the pharmaceutical industry. Ms Simpson was instrumental in the initial development and subsequent growth of Compounds Australia from its inception to now a fully operational and busy compound management facility. Ms Simpson holds a Bachelor of Science with Honours and a Graduate Diploma in Project Management; her expertise is primarily in the areas of chemistry and biochemistry.

    Sue Crimmin

    Vice President Sample Management Technology

    GlaxoSmithKline

    Michael Jobling, Ph.D.

    Vice President, Sample Management

    Evotec

    Patrick Faloon, Ph.D.

    Principal Scientist

    Biogen

    Travis Mathewson, Ph.D.

    Senior Principal Scientist

    Pfizer Inc

    Lane Milde, Ph.D.

    Senior Scientist

    Pfizer

    Melissa Bennion

    Scientist I

    Biogen

    Steve McCoy, Ph.D.

    Head of Sales

    LabVoice

    Susana A. Morais, Ph.D.

    Assoc. Prin Scientist

    Merck & Co., Inc.

    Christian Ferrante, Ph.D.

    Scientific Associate Director

    Bristol Myers Squibb

    Brenda Li-Johnson, Ph.D.

    Screening Profiling and Mechanistic Biology - Sample Management UP Group Leader

    GlaxoSmithKline

    Marianne K. Henderson, M.S., C.P.C.

    Senior Advisor

    Center for Global Health/National Cancer Institute/NIH/DHHS

    Marybeth Burton

    Executive Director, Discovery Sample Management

    MSD

    Marybeth Burton leads MSD’s global Discovery Sample Management group based in the US at the Rahway, New Jersey site. She is responsible for small molecule compound management, chemical inventory management and compliance, and chemistry operations. Her group monitors compound collection quality and participates in efforts to continuously improve both stewardship and composition of MSD's small molecule compound collection. Marybeth also has responsibility for management of discovery biological samples within MSD and has collaborated with colleagues in clinical research to develop an overall bio-repository strategy. Marybeth has been involved with process optimization efforts and development of new workflows to support changing sample management needs resulting from globalization of drug discovery efforts. Her team is also currently responsible for managing external chemistry partner relationships and establishing global compound logistics workflows.

    Prior to her tenure at MSD, Marybeth led the compound management group at Schering-Plough. Marybeth holds a B.A. in Biology and an M.S. in Information Science.

    David Hayes, Ph.D.

    Director, North American Operations

    Specs

    Jeff Chin

    Senior Scientist

    Pfizer

    Heather Colvan, Ph.D.

    Director of Operations

    Simplicis

    Rob Perkinson

    Executive Director of Global Biorepository Services

    TMRW Life Sciences

    Rob Handfield, Ph.D.

    Bank of America University Distinguished Professor of Supply Chain Management

    North Carolina State University

  • Contains 1 Component(s)

    This two-hour introductory workshop provides teams at all levels across an organization with an overview of how to define, clarify and understand the value proposition of an innovation effort in a way that gives teams the confidence required to commit fully to the objective.

    Understanding the value proposition of a product, service or an organization is key to understanding the right business model to apply in any given scenario. Clarity around what the value proposition is – in the eyes of the customer or user – and why it matters is absolutely essential to drive growth. Having the ability to define, clarify and understand the value proposition can therefore drive business model innovation efforts for customers and businesses (both startups and existing organizations).

    This two-hour introductory workshop provides teams at all levels across an organization with an overview of how to define, clarify and understand the value proposition of an innovation effort in a way that gives teams the confidence required to commit fully to the objective. This workshop provides a 'pracademic' approach to learning through the use of tools and methodologies that can be applied on a continuous basis to keep organizations relevant and successful.

    Who Should Attend
    Ideal participants are project/program managers, leaders and other internal stakeholders that have influence over the creation or implementation of a new product, service or process. Stakeholders include product line managers, portfolio managers and leaders of product development teams in addition to project team members. This workshop is also extremely beneficial for entrepreneurs and leaders of early stage companies seeking to ensure clarity around their customer value proposition. The learning from this program is applicable also to those in research institutions as well as research-led higher education organizations.

    Workshop Benefits
    For a newly formed business or for those contemplating starting a business or a spin-off activity, this workshop helps aspiring entrepreneurs, intrapreneurs and innovators understand what their organization must do to be successful. For an existing business, this workshop ensures internal stakeholders are aligned with those critical customer and company objectives before significant capital is deployed in pursuit of the innovation.

    Workshop Topics
    Define
    The Customer Value Proposition defines why a customer will utilize your innovation and how they will derive value. This enables leaders to align their organization more effectively with those critical value drivers for the development and implementation of a product, service or business process. You will begin this workshop by learning to create Customer/Innovation Value Propositions that will help to guide your project to success.

    Clarify
    The next methodology covered is the product/market fit and the value your organization can offer different customer segments. You will learn about and acquire the tools and thinking that can help you enhance your Customer and Innovation Value Propositions, clarifying what your organization must do to allow your project to succeed.

    Understand
    These elements can speed up delivery of project and organization objectives, ensuring a deep understanding of the value proposition and positioning of the organization that are critical from an execution perspective and that fully support the realization of the Customer and Innovation Value Propositions. At the conclusion of the workshop, you will have the tools to ensure your organization has the clarity and confidence to gain the commitment of your team to deliver the desired innovation.

    Gordon McConnell, M.B.S.

    Co-founder and Chief Innovation Officer

    Arkane Innovation

    Gordon McConnell is a co-founder and Chief Innovation Officer at Arkane Innovation, an advisory, consulting and training company that works with higher education, government, NGOs and industry on innovation management and entrepreneurship ecosystems strategy, programs and implementation. He has a significant history of working in entrepreneurship, innovation, social enterprise and economic development. McConnell was a Visiting Director of Innovation and Professor of Entrepreneurship at Robert Gordon University (RGU) in the UK and was previously VP of Commercial and Regional Innovation at RGU. Launched in September 2018, the innovation activities in RGU won the Scottish Herald ‘Higher Education Award for Outstanding Business Engagement’ in June 2019 and was short-listed as ‘Outstanding Entrepreneurial University’ in the UK 2020 by the Times Higher Education (THE).

    Prior to RGU, McConnell was the Head of the Entrepreneurship Center and Professor of Practice in Entrepreneurship at King Abdullah University of Science and Technology (KAUST) in Saudi Arabia. Before Saudi Arabia, he was Associate Vice President of Innovation and Entrepreneurship at Arizona State University and Principal Investigator of the ASU Center of Excellence in Technology Transfer. His new initiatives at ASU won the U.S. award for ‘Most Promising Technology Based Economic Development’ in 2013 from the SSTI and a University Economic Development Association Award in 2014. He has developed and taught entrepreneurship, social entrepreneurship and management curriculum in a number of colleges and universities. McConnel was part of the UK/Ireland Strategy Practice at Accenture and started his career in Westinghouse. He has spoken at a number of leading conferences including at the Kauffman Foundation, the Association of University Technology Managers (AUTM) Annual Conference and the Global Competitiveness Forum.

    Mark Crowell, R.T.T.P.

    Co-Founder and President

    Arkane Innovation

    Mark Crowell is a Co-Founder and President of Arkane Innovation, an international advisory services firm (based in Ireland, the UK and the US) focused on entrepreneurship, innovation ecosystems (including startup programs), innovation strategy, accelerator programs, research commercialization and spinouts, innovation district planning and economic development initiatives. Crowell is also Executive Entrepreneur in Residence for the Eshelman Institute for Innovation (EII) at the UNC Eshelman School of Pharmacy. EII is supported by a gift of $100 million (from Dr. Fred Eshelman) and is focused on developing new strategies and partnerships to drive early stage academic discoveries more effectively and more urgently through translational research to early stage clinical and commercial application.

    Crowell’s extensive consulting includes serving as a Senior Innovation Consultant for the World Bank and for the San Diego Biomedical Research Institute. Other clients and projects include the Qatar Foundation, TEConomy Partners, the University of California President’s Office and the Arkansas Research Alliance. He also is an inaugural Board member of Med Aditus, a newly formed global non-profit focused on sub-Saharan Africa and building a state-of-the-art pharmaceutical product development and manufacturing facility and a secure distribution network with the end goal of improving patients’ access to affordable high-quality medicines.

    Crowell has more than 32 years of experience in academic innovation, technology transfer and translational partnerships. He served as Vice President for Innovation and Economic Development at the King Abdullah University of Science and Technology (KAUST) in Saudi Arabia, founding Executive Director of UVa Innovation at the University of Virginia and chief technology transfer and business development officer at The Scripps Research Institute, the University of North Carolina at Chapel Hill, NC State University and Duke University. Crowell was President of the Association of University Technology Managers (AUTM) in 2005, Chair of the Technology Transfer Committee of BIO (2009-2014) and co-chair of the Research Committee of the APEC Life Science Innovation Forum. In 2013, he received the Bayh-Dole Award from AUTM in recognition of his lifetime contributions to advancing academic innovations.

  • Contains 11 Component(s)

    Students and early-career professionals acquire a basic understanding of how target engagement and validation “fits” into early drug development, techniques used, and how this allows for more complex MOA studies.

    The most prevalent cause of new drug failure is lack of demonstration of target engagement and therapeutic effect. Students and early-career professionals need to acquire a basic understanding of how target engagement and validation “fits” into early drug development, techniques used, and how this allows for more complex MOA studies.

    Drugs interact with living breathing physiology and can present different profiles of activity in organs of varying sensitivity; pharmacology furnishes scales of activity to turn 'descriptive data' (what we see in one experiment) to 'predictive data' (what will be seen under all conditions in vivo).

    Who Should Attend
    Biologists involved in drug discovery
    Medicinal chemists
    Pharmacology students
    Academic pharmacologists

    Course Benefits
    Gain new insights into state-of-the-art ideas on drug targets and their association with therapeutic opportunities
    Learn new tools to quantitatively assess molecular effects on drug targets
    Learn how parameters from these methods can predict activity in all systems
    Define new vistas around old targets to better define chemical targets for receptors

    Course Topics
    Systems- vs. target-based research
    Target validation: eg.CCR5 HIV
    Role of Knock outs
    Drugging Targets, HTS, virtual screening
    Drugging orphans (constitutive screening)
    New chemical entities (esp. allosteric modulators)
    50% efficacy failures: reasons why and ways forward
    Target vs. pathway validation and biased signaling
    Demonstrating target engagement in vitro
    Demonstrating target engagement in vivo
    Linking target engagement with therapeutic effect

  • Contains 14 Component(s)

    Learn more about the various AI tools available today as well as discuss future drug discovery collaborations involving the cutting-edge advances in AI, machine learning and computational science.

    Learn more about the various AI tools available today as well as discuss future drug discovery collaborations involving the cutting-edge advances in AI, machine learning and computational science.

    Daniel Ting, M.B.B.S., Ph.D.

    Director of Singapore Health Service (SingHealth) AI Program, Head of AI and Digital Innovation

    Singapore National Eye Centre

    Associate Professor Daniel Ting is the Director of Singapore Health Service (SingHealth) AI Program, Head of AI and Digital Innovation in Singapore Eye Research Institute (SERI), Associate Professor in Ophthalmology with Duke-NUS Medical School Singapore. At the global setting, Dr Ting serves in several AI executive committee (American Academy of Ophthalmology, STARD-AI, QUADAS-AI, DECIDE-AI), AI editorial boards (Associate Editors for Nature Digital Medicine, Frontiers in Medicine and Frontiers in Digital Health; and Chair of AI and Digital Innovation Standing Committee, Asia-Pacific Academy of Ophthalmology. In 2017, he was also the US-ASEAN Fulbright Scholar who visited the Johns Hopkins University to deepen the AI collaboration between US and the ASEAN regions. 

    To date, he has published >200 peer-reviewed papers in highly prestigious journals such as JAMA, NEJM, Lancet, Nature Medicine, Nature Biomedical Engineering, Lancet Digital Health and etc. In 2021, he is also ranked the world’s most influential deep learning researcher across all domains in healthcare for the past 10 years (2010-2021) by the ExpertScape. 

    For the accomplishment, Dr Ting was recognized by many top-tiered international AI and ophthalmology societies in winning many prestigious scientific awards, including the MICCAI OMIA Prestigious Achievement Award (2020), ARVO Bert Glaser Award for Innovative Research in Retina (2020), USA Macula Society Evangelos Gragoudas Award (2019), APAO Young Ophthalmologist’s Award (2018), APTOS Young Innovator Award (2017) and etc. 

    With the advancement of AI technology, Daniel hopes to harness the power of digital technology, including big data, deep learning and blockchain, to  improve patients’ outcome, experience, reduce health economic burden and more importantly, narrow the gap of inequality of health care access, standard and delivery globally.

    Kerry Gilmore

    Assistant Professor of Chemistry

    University of Connecticut

    Dr. Kerry Gilmore is an Assistant Professor of Chemistry at the University of Connecticut. He grew up in Brewster, Massachusetts and attended Roger Williams University obtaining bachelors degrees in Biology and Chemistry. He received his Ph.D. in 2012 from Florida State University studying cyclization reactions, during which time he was a Fulbright Scholar working at the CNR in Bologna, Italy.  He then moved to the Max-Planck Institute of Colloids and Interfaces for postdoctoral work, and was group leader of the flow chemistry group from 2014-2020. In 2020 he moved to the University of Connecticut where he is an Assistant Professor. His current research interests include the development of technology and approaches to advance methodologies of small molecule synthesis, as well as to utilize computational methods and machine learning to better understand and predict the selectivity of organic reactions. He recently won the ACS 2021 Award for Affordable Green Chemistry.

    Ola Engkvist, Ph.D.

    Head Molecular AI

    AstraZeneca R&D

    Dr Ola Engkvist is head of Molecular AI in Discovery Sciences, AstraZeneca R&D. He did his PhD in computational chemistry at Lund University followed by a postdoc at Cambridge University.  After working for two biotech companies he joined AstraZeneca in 2004. He currently lead the Molecular AI department, where the focus is to develop novel methods for ML/AI in drug design , productionalize the methods and apply the methods to AstraZeneca’s small molecules drug discovery portfolio. His main research interests are deep learning based molecular de novo design, synthetic route prediction and large scale molecular property predictions. He has published over 100 peer-reviewed scientific publications. He is adjunct professor in machine learning and AI for drug design at Chalmers University of Technology and a trustee of Cambridge Crystallographic Data Center. 

    Rafael Gomez-Bombarelli, Ph.D.

    Toyota Assistant Professor in Materials Processing

    MIT DMSE

    Rafael Gomez-Bombarelli is the Toyota Assistant Professor in Materials Processing in MIT’s Department of Materials Science and Engineering. Gomez-Bombarelli is interested in fusing machine learning and atomistic simulations for designing materials and their transformations. His group works across molecular, crystalline and polymer matter, combining novel computational tools in optimization, inverse design, surrogate modeling and active learning with simulation approaches like quantum chemistry and molecular dynamics. Through collaborations at MIT and beyond, his group helps develop new practical materials such as therapeutic peptides, organic electronics for displays, electrolytes for batteries, and oxides for sustainably catalysis. Gomez-Bombarelli’s work has been featured in the MIT Technology Review and Wall Street Journal. He also co-founded Calculario, a materials discovery company that leverages quantum chemistry and machine learning to target advanced materials in high-value markets. He earned a BS, MS, and PhD in chemistry from Universidad de Salamanca, followed by postdoctoral work at Heriot-Watt University and Harvard University.

    Payel Das, Ph.D.

    IBM Research

    Dr. Payel Das is a Principal Research Staff Member and a manager at IBM Research AI, IBM Thomas J Watson Research Center. She has also been an adjunct associate professor at the department of Applied Physics and Applied Mathematics (APAM), Columbia University. She received her Ph.D. on theoretical biophysics from Rice University, Texas. Currently, she leads research on trustworthy AI in the low-data regine and machine creativity. A central focus is on developing controllable generative AI and efficient black-box optimization techniques. The goal is to enable reliable modeling of complex systems and efficient synthesis of novel and useful designs for various downstream business and scientific applications, including drug discovery and material design. 

     
    Das has co-authored over 40 peer-reviewed publications and several patent disclosures, given dozens of invited talks at several university colloquiums, department seminars, top rated conferences, and workshops. She served as the editorial advisory board member of the ACS Central Science journal. She is the recipient of two IBM Outstanding Technical Achievement Awards (the highest technical award at IBM), two IBM Research Division Awards, one IBM Eminence and Excellence Award, and six IBM Invention Plateau Awards. 

    Dean Ho, Ph.D.

    Head, Department of Biomedical Engineering

    National University of Singapore

    Provost’s Chair Professor

    Director, The N.1 Institute for Health (N.1)

    Director, The Institute for Digital Medicine (WisDM)

    Head, Department of Biomedical Engineering

    iao Liu, M.B.ChB., Ph.D.

    Ophthalmologist

    University Hospitals Birmingham NHS Foundation Trust

    Dr Xiao Liu is an ophthalmologist and a post doctoral researcher at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust. She is interested in evidence standards for AI in healthcare, to ensure AI innovations can safely and effectively improve patient care. Xiao co-led the development of SPIRIT-AI and CONSORT-AI, the first international reporting standards for clinical trials of AI interventions, and is working with other AI reporting standards in development, including STARD-AI, DECIDE-AI and TRIPOD-AI. She also works with regulatory and commissioning bodies, including MHRA, NICE, the UK National Screening Committee and the WHO/ITU AI4H focus groups, on their approaches to evaluating AI in healthcare.

    Edward Chow, Ph.D.

    Editor-in-Chief, SLAS Technology; Associate Professor Cancer Science Institute of Singapore

    National University of Singapore

    Associate Professor Edward Kai-Hua Chow is a Principal Investigator at National University of Singapore (NUS) in the Cancer Science Institute of Singapore and the Department of Pharmacology. He is also the Research Director for the Institute of Digital Medicine (WisDM) and Dept. of Pharmacology. He received his B.A. in Molecular and Cellular Biology from the UC Berkeley and his Ph.D. at UCLA. Prior to joining NUS, A/P Chow was an American Cancer Society Postdoctoral Fellow under the guidance of Prof. J. Michael Bishop (1989 Nobel Prize in Physiology or Medicine) at UCSF. His research group is interested in understanding how to treat specific oncology patients or patient subtypes as well as the oncogenic drivers that determine subtype-specific therapy. In particular, his group is interested in applying engineering-based analytics towards personalised and precision drug combination design. Through the development of quadratic phenotypic optimisation platform (QPOP), his group has demonstrated that drug combination design for specific disease indications as well as specific patient groups can be quickly achieved in a cost, time and sample efficient manner. With an emphasis on haematological malignancies and gastrointestinal cancers, this work has been translated into multiple clinical studies as well as part of the NUS start-up, KYAN Therapeutics.

    Elodie Pronier, Ph.D.

    Lead Biologist

    Owkin

    Elodie Pronier, PhD, Lead Biologist, Owkin graduated from Université Denis Diderot (Paris 7) with a European Magister in Genetics, before completing her PhD in Oncology and Hematology at Institut Gustave Roussy. There, she focused on epigenetic mutations involved in leukemia development. Elodie then moved to New York as a postdoctoral research fellow at the Memorial Sloan Kettering Cancer Research in Ross Levine’s laboratory, where she co-led several projects on the genetics of leukemia. She is now a Lead Biologist within Owkin’s Biotech team. She is in charged of creating our early drug discovery pipeline. 


    Lukas Pelkmans

    Endowed Research Chair

    University of Zurich

    Lucas Pelkmans studied Medical Biology at the University of Utrecht in The Netherlands, and did his PhD in Biochemistry at the ETH Zurich in Switzerland. He was then a postdoctoral fellow at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany. In 2005, Lucas Pelkmans returned to Switzerland to start his research group in image-based systems biology at the ETH Zurich as an assistant professor, and was elected to the Ernst Hadorn Foundation-endowed Chair at the University of Zurich in 2010, where he has his research group since then. Lucas Pelkmans has received multiple awards for his pioneering work to establish the field of image-based systems biology, has received junior, consolidator, and advanced ERC grants, and is a member of EMBO.

    Leonidas Bleris, Ph.D.

    Cecil H. and Ida Green Chair in Systems Biology Science and Professor

    The University of Texas at Dallas

    Leonidas Bleris is a Cecil H. and Ida Green Chair in Systems Biology Science and Professor with the Bioengineering Department of the University of Texas at Dallas. Before joining UTD, Bleris was a Postdoctoral Fellow at the FAS Center for Systems Biology at Harvard University. Bleris earned a Ph.D. in Electrical Engineering from Lehigh University in 2006. He received a Diploma in Electrical and Computer Engineering in 2000 from Aristotle University of Thessaloniki, Greece. Bleris was awarded the Christine Mirzayan Science and Technology Policy Graduate Fellowship from the National Academy of Science (NAS), and served with the Board of Mathematical Sciences and their Applications. During 2009-2010, Bleris was a Visiting Scientist at the FAS Center for Systems Biology at Harvard University, and an Independent Expert with the European Commission under the "Science, Economy and Society" directorate. Bleris served as the University of Texas at Dallas Representative for the 2011-2012 Tuning Oversight Council for Engineering and Science, Committee on Bioengineering, and received the 2014 Junior Faculty Research Award from the Erik Jonsson School of Engineering and Computer Science. In 2018 Bleris was awarded a Cecil H. and Ida Green Chair in Systems Biology Science. His research has focused on systems biology, mammalian synthetic biology and genome editing.

    Chris Bakal

    Professor of Cancer Morphodynamics

    Institute of Cancer Research

    Chris Bakal is the Professor of Cancer Morphodynamics at the Institute of Cancer Research in London, UK, where he leads the Dynamical Cell Systems Laboratory. His team aims to understand how cancer is driven by changes in cell shape. 

    Chris was born in Calgary, Canada. He received his BSc in Biochemistry from the University of British Columbia, and his PhD in Medical Biophysics from the University of Toronto. Chris’ postdoctoral work was performed in Department of Genetics at Harvard Medical School, and the Computer Science and Artificial Intelligence Laboratory (CSAIL) at the Massachusetts Institute of Technology (MIT). In 2007, Chris was named as one of the most promising postdoctoral fellows or junior faculty members at Harvard Medical School by the Dorsett L. Spurgeon award. After being awarded a Wellcome Trust Career Development Fellowship, Chris established his laboratory at the Institute of Cancer Research in London in 2009. In 2015 he was awarded the prestigious Cancer Research UK Future Leaders Prize.

    Outside of science Chris is competitive track cyclist, a former national-level runner, and a former world-ranked downhill ski racer. Chris has run a mile in just over 4 min, and aims to compete in the Ironman next year.

    Finton Sirockin, Ph.D.

    Associate Director

    Novartis

    Finton Sirockin, PhD, is Associate Director in Global Discovery Chemistry in Novartis, based in Basel.

    Finton is a theoretical chemist / molecular modeller by training with a keen interest in exploring how data science can make drug discovery more efficient.
    He obtained his Ph D. in Theoretical Chemistry from the University Louis Pasteur of Strasbourg in Prof. Martin Karplus group under the supervision of Prof. Annick Dejaegere, in 2003. After a year of Postdoc working on structural aspects of bioinformatics he joined Novartis’ CADD group in Basel. He delved into cheminformatics and machine learning through their application in MedChem projects.
    He is providing MedChem project support in different Disease Areas. Since 2020, he is leading the Project Digital Lead initiative which fosters Data Science and Digital Tools literacy in the Medicinal Chemistry community in NIBR. He is also providing CADD support in MedChem projects and a machine learning collaboration applied to chemistry. Finally he is co-leading, at the MedChem project application level, the Generative Chemistry exploration collaboration between Microsoft Research and Novartis.

    David Leslie

    Ethics Lead

    The Alan Turin Institute

    Dr David Leslie is the Ethics Theme Lead within the public policy programme at the Alan Turing Institute. He is the author of the UK Government’s official guidance on the responsible design and implementation of AI systems in the public sector, Understanding artificial intelligence ethics and safety (2019) and a principal co-author of Explaining decisions made with AI (2020), a co-badged guidance on AI explainability published by the Information Commissioner’s Office and the Alan Turing Institute. He is PI of a UKRI-funded project called PATH-AI: Mapping an Intercultural Path to Privacy, Agency and Trust in Human-AI Ecosystems, which is a research collaboration with RIKEN,  Japan, as well as of a BEIS and GPAI funded research project entitled Advancing Data Justice Research and Practice. David is also lead author of “Does AI stand for augmenting inequality in the COVID-19 era of healthcare” (2021) published in the British Medical Journal and the lead author of Artificial intelligence, human rights, democracy, and the rule of law (2021), a primer translated into Dutch and French. His other recent publications include the Harvard Data Science Review article, “Tackling COVID-19 through responsible AI innovation: Five steps in the right direction,” (2020), Understanding bias in facial recognition technologies (2020), and “The Arc of the Data Scientific Universe,” (2021) also published in the HDSR. 

     
    Before joining the Turing, David taught at Princeton’s University Center for Human Values. Prior to teaching at Princeton, David held academic appointments at Yale and at Harvard, where he received over a dozen teaching awards. He now serves as an elected member of the 9-person Bureau of the Council of Europe’s Ad Hoc Committee on Artificial Intelligence (CAHAI). He is on the editorial board of the Harvard Data Science Review and is a founding editor of the Springer journal, AI and Ethics.

    Brent Mittelstadt, Ph.D.

    Senior Research Fellow

    University of Oxford

    Brent Mittelstadt is a Senior Research Fellow in data ethics at the Oxford Internet Institute. He is an ethicist and philosopher focusing on auditing, interpretability, and ethical governance of complex algorithmic systems, as well as data protection, privacy, and non-discrimination law. He coordinates the Governance of Emerging Technologies (GET) research programme at the OII, which investigates ethical, legal, and technical aspects of AI, machine learning, and other emerging technologies.

    Carlos Maria Galmarini, M.D., Ph.D.

    CEO

    Topazium Artificial Intelligence

    Carlos María Galmarini is Topazium’s founder. He earned his Medical Degree from the University of Buenos Aires (Argentina), after which he completed an internship in clinical oncology at Marie Curie Cancer Center (Buenos Aires). He pursued two post-doctoral fellowships in oncology at Los Angeles City of Hope Cancer Center (USA) and at Léon Bérard Cancer Center (Lyon, France). He obtained his PhD in oncology and his qualification to lead research teams (HDR) at Claude Bernard Lyon-1 University (Lyon, France). Carlos María practiced medicine both at the Marie Curie and Carlos G. Durand Hospitals in Buenos Aires for several years. He has also held positions as a medical researcher in oncology at Lyon Rockefeller Medical School and in Lyon-Sud Medical School (France), where he was appointed Associate Professor. In 2008 he joined PharmaMar (Madrid, Spain) as Head of Cell Biology and Pharmacogenomics, where he was in charge of drug screening, biochemistry, molecular biology and pharmacogenomics areas. He has authored over 130 publications across leading international scientific journals. In recent years, he devoted his research to the application of artificial intelligence in healthcare, molecular biology and other related-medical fields, particularly, in the generation of diagnostic assistance and predictive tools applied to clinical trials and real-world data.

  • Contains 17 Component(s)

    The SLAS 2021 European Sample Management Symposium welcomes all compound and sample management professionals – from bench scientists to senior leaders – to obtain fresh perspectives and share innovative solutions to challenges in these domains.

    Sample management has become increasingly important in every phase of chemical and biological discovery. Control over factors like sample quality, process efficiency, metadata and miniaturization must be achieved to accelerate both academic and industrial programmes. Further complexity arises in maintaining these factors when collaborating with an external research partner. The SLAS 2021 European Sample Management Symposium welcomes all compound and sample management professionals – from bench scientists to senior leaders – to obtain fresh perspectives and share innovative solutions to challenges in these domains.

    Andreas Nixdorf, Ph.D.

    SGS Institut Fresenius GmbH

    Kerstin Hermuth-Kleinschmidt, Ph.D.

    Owner

    NIUB Nachhaltigkeitsberatung

    Kerstin Hermuth-Kleinschmidt holds a PhD in chemistry. After several years in the life sciences industry as account manager and in technical customer support, she turned her attention to the topic of sustainability and obtained an additional qualification in the field of "Environmental Management and Environmental Economics" at the University of Koblenz-Landau. The focus of her work is the implementation and monitoring of sustainability processes in the life sciences – in the lab as well as in life sciences companies. As a speaker and author of publications, she focuses on various aspects of sustainability, especially on the topic "Sustainability in research and laboratory". She also participated in the development of EGNATON-CERT, the first certification system for sustainable laboratory technologies, and is now part of the auditing team.

    Oliver Peter, Ph.D.

    Director, Group Leader Biology Technologies and Lead Discovery, Drug Discovery Biology

    Idorsia Pharmaceuticals Ltd.

    Alexander Knaupp, Dipl. Ing.

    Roche Diagnostics GmbH Deutschland

    Nicolas Zorn, Ph.D.

    Head Compound Library Enhancement and Logistics

    Hoffmann La Roche

    Nicolas Zorn received his Ph.D. in Organic and Synthetic Chemistry from the University of Paris 6 and worked in the industry for ten years as a medicinal and then computational chemist across several disease therapeutic areas. He joined Roche in 2014 in the Computer Aided Drug Design team and now heads the Compound Library Enhancement and Logistics team since December 2017. Current roles include the development of new hit finding workflows spanning from compound logistics to data analysis workflows as well as strategy and tactics for small molecule compound library optimization and application to screening.

    Jeanette Andersen, Ph.D.

    UiT – The Arctic University of Norway

    Kristen Nailor

    Genentech

    Manuela Beil-Peter

    Director Business Sector Liquid Handling and Automation

    Analytik Jena AG

    Agnes Bombrun Sauer

    Head of Ingredients Research - Fragrance S&T

    Givaudan

    Since 2014, I am in charge of the Ingredients Research in the Fragrance & Beauty division of Givaudan, based in Zurich, Switzerland. My main responsibilities are to drive dynamically a rich and competitive pipeline of sustainable innovation for the perfumers, which consists of delivering the best Fragrance molecules and processes by green chemistry and biotechnology.

    I started out my career in the pharmaceutical industry. By training I am a chemical engineer (Lyon, France) and an organic chemist with a PhD (Emory University, Atlanta). I was Director of Medicinal Chemistry for Merck Serono, Geneva and I also worked for GSK, France and Affymax, California.

    Daniel Juchli

    Wega Informatik

    Jason Meredith, B.Sc.

    Head Of Software Product Management

    Tecan Schweiz AG

    Jason Meredith works for Tecan Switzerland as Head of Software Product Management. He graduated in 1989 with a 2.1 (Honours) degree in Computer Systems Engineering, from University College of North Wales in the United Kingdom. Initially he worked for a start up company in North Wales later purchased by Diagnostics Products Corporation (now part of Siemens), developing software for early robotic sample processors and automation. Jason joined Tecan in 1999, and took on Software Product Management for Freedom EVOware and associated add-ons and interfaces. As Head of Software Product Management he is responsible for managing Tecan’s automation software products for the Life Science Business.

    Fred Bost

    LabVoice

    Joe Bradley

    Scitegrity

    Andreas Traube

    Fraunhofer IPA

    Silvio Di Castro, M.Sc.

    AstraZeneca

    A chemical engineer by training, Silvio joined Compound Management at AstraZeneca in 2002. During the time at AZ, Silvio has developed a deep expertise in laboratory automation, from programming simple benchtop units to developing large automated platforms for high-throughput screening. Working across functions and countries, Silvio has developed a large network of strong connections, and implemented solutions for automated sample handling in several areas of the business.

    In his current role  as associate principal scientist, Silvio is leading the deployment of the first fully acoustic Sample Management system in the world, developed by AZ in a collaborative
    partnership with Labcyte and Brooks. He is also aligned with global initiatives to improve sample storage, handling and usage of new therapeutic modalities (peptides, RNAs, DNAs and more).

    Prior to joining AstraZeneca, Silvio gained an MSc in Chemical Engineering at the "Federico II" University, Naples (Italy), under the supervision of Prof. Guido Greco.

    Chris Brankin

    AstraZeneca

    Melanie Leveridge, BSc. Hons.

    Melanie Leveridge, BSc. Hons.

  • Contains 110 Component(s)

    Sessions recorded at SLAS2020 International Conference & Exhibition January 27-29, 2020 San Diego, CA, USA

    The SLAS2020 course package contains 118 presentations including:

    95 presentations from ten scientific tracks
    Advances in Bioanalytics and Biomarkers
    Assay Development and Screening
    Automation and High-Throughput Technologies
    Biologics Discovery
    Cellular Technologies
    Data Analysis and Informatics
    Drug Target Strategies
    Micro- and Nanotechnologies
    Molecular Libraries
    Precision Medicine Technologies
    2 keynote speakers
    3 Ignite Panel Discussions
    4 Ignite Academic Collaboration Presentations 
    14 Ignite Award Finalist Presentations

    Based on presenter permission, 118 of the 161 total SLAS2020 presentations are available on-demand.
    The SLAS Scientific Program Committee selects conference speakers based on the innovation, relevance and applicability of research as well as those that best address the interests and priorities of today’s life sciences discovery and technology community. All presentations are published with the permission of the presenters.

    Nicola Richmond, Ph.D.

    Director

    GlaxoSmithKline

    Nicola trained as an algebraist up to Ph.D. level then moved into chemoinformatics via a two year role in the Statistics and Modelling Group at Unilever R&D. After completing a post-doctoral fellowship with Prof. Peter Willett at the University of Sheffield, Nicola joined GSK’s then Cheminformatics group in 2004 where she held a number of roles including developing methodologies for chemical database searching and hit identification in the presence of process error for high-throughput, high-content screening and both supporting and leading early, small molecule, drug discovery programmes. Nicola then joined one of GSK’s fledgling data science groups and led the Biopharm Digital, Data and Analytics focus area, overseeing a number of high-impact projects and continuing with methods development. She is now a director in the newly-formed AI and Machine Learning team where she is predominantly focussed on AI research.

    Ellen Berg, Ph.D.

    Chief Scientific Officer, Translational Biology

    Eurofins Discovery

    Ellen L. Berg, PhD, is Chief Scientific Officer, Translational Biology at EurofinsDiscovery. She leads the scientific direction of the company’s in vitro phenotypic profiling services including the BioMAP® human primary cell-based assay platform. Dr. Berg was co-founder and CSO of BioSeek (acquired by DiscoverX) and before that led a research team developing biotherapeutics at Protein Design Labs (now AbbVie). She received her PhD from Northwestern University and was a postdoctoral fellow at Stanford University. Dr. Berg has served in various positions with the Society of Laboratory Automation and Screening (SLAS), is a board member of the American Society for Cellular and Computational Toxicology (ASCCT), and a member of the Society of Toxicology (SOT) and Inflammation Research Association. Her research interests include drug and toxicity mechanisms of action, phenotypic drug discovery, and predictive toxicology. Dr. Berg holds several patents in the field of inflammation, and has authored over 80 publications.

    Stephen Previs

    Merck

    Responsible for conducting pharmacology and mechanism of action studies, activities span early discovery target screening and development of hits for in vivo studies. Primarily involved in experimental design strategies and interpretation of metabolic flux data.

    Loren Olson

    SCIEX

    Martin Giera, Ph.D.

    Head of the Metabolomics Group at the Center for Proteomics and Metabolomics

    Leiden University Medical Center

    Martin studied pharmacy in Heidelberg and Munich. He is the head of the Metabolomics group at the Center for Proteomics and Metabolomics at the Leiden University Medical Center (LUMC). He holds a PhD in Pharmaceutical Chemistry obtained from the Ludwig-Maximilians-University in Munich (Germany) . With a postdoctoral fellowship (DAAD stipend), he joined the group of Prof. Hubertus Irth at the VU University Amsterdam. Following a research stay in the laboratory of Prof. Charles Serhan at Harvard Medical School, he moved to the LUMC where he today heads the Metabolomics group. He is editor of the book “Clinical Metabolomics”. Martin is a permanent committee member of the inter-disciplinary panel of the FWO and served in several EU committees. His main interests lie in clinical and fundamental disease-related research, using metabolomics-based approaches and notably lipidomics.

    Milan Mrksich, Ph.D.

    Henry Wade Rogers Professor

    Northwestern University

    Dr. Milan Mrksich, the inventor of the SAMDI technology, is the Henry Wade Rogers Professor at Northwestern University and holds appointments in the departments of chemistry, biomedical engineering and cell biology. His research combines synthetic chemistry with materials science to study important problems in cell biology. Dr. Mrksich develops biochips for a host of biological and biotechnological applications and develops mimics of the extracellular matrix for studies of cell adhesion and migration.

    Having authored 150 peer-reviewed articles, many based on the SAMDI technology, Dr. Mrksich was named by Technology Review magazine as one of the 100 Top Young Innovators in 2002. He is also a recipient of the ACS Arthur C. Cope Young Scholar Award (2003) and a Fellow, American Institute for Medical and Biological Engineering (2012).

    Dr. Mrksich has a doctorate in chemistry from California Institute of Technology and served a postdoctoral fellowship at Harvard University.

    Aarti Kawatkar

    Senior Scientist

    AstraZeneca

    Aarti Kawatkar is a Senior Scientist at AstraZeneca in the Chemical Biology and Proteomics Group of Discovery Sciences since 2013. Before that she was a lead chemist in the FBLG group and medicinal chemist in Oncology at AstraZeneca. During this time she has contributed to several drug discovery projects making it to the clinic and developed assays such as CEllular Thermal Shift Assay (CETSA) and in-cell Chemoproteomics to measure cellular target engagement and target validation for multipass transmembrane protein receptors. For this work she was the recipient of ”Emerging Scientist” award at AstraZeneca in 2016. She is a module leader for Proteomics course at Cold Spring Harbor Labs where participants get in-depth knowledge about chemoproteomics techniques routinely used in industry. Before joining AstraZeneca she worked at Vertex Pharmaceuticals as a medicinal chemist. She obtained her M.S. in Organic Chemistry from the UGA, Athens in 2005 with Prof. Geert- Jan Boons.

    Joshua L. LaBaer, M.D., Ph.D.

    Executive Director for the Biodesign Institute

    Arizona State University

    Joshua L. LaBaer, M.D., Ph.D., a leading researcher in cancer and personalized medicine, is the executive director for the Biodesign Institute at Arizona State University.

    Joshua LaBaer is one of the nation’s foremost investigators in the rapidly expanding field of personalized medicine. His efforts involve the discovery and validation of biomarkers — unique molecular fingerprints of disease — that can provide early warning for those at risk of major illnesses, including cancer and diabetes.

    LaBaer also serves as director of Biodesign’s Virginia G. Piper Center for Personalized Diagnostics, where he leads a staff of nearly 100 faculty and biologists, microbiologists, engineers, informaticists and students who combine their expertise to find ways to decrease the impact of human disease. As director, he holds the university’s first Piper Chair in Personalized Medicine.

    Andrea Peier

    Merck

    Over 15 years in industry working in various therapeutic areas with a focus on in vitro models for disease. Currently leading cell-based assay development and screening for target- and phenotypic-based screens.

    Laurie Parker

    University of Minnesota

    Dr. Parker was trained as a synthetic chemist before moving into chemical biology, proteomics, and kinase assay design. Her lab develops new substrates and read-out methods for measuring kinase activity in vitro and in live cells.

    Gianluca Pegoraro

    National Cancer Institute

    Dr. Pegoraro heads the High-Throughout Imaging Facility (HiTIF), which provides CCR investigators with the expertise and the technology needed to set-up, optimize and implement high-content imaging (HCI) assays. HCI assays are used to analyze large numbers of experimental conditions, such as in high-throughput RNAi or chemical compounds screens. In addition, the HiTIF applies HCI in combination with single-cell image and data analysis to quantify exceedingly rare but biologically important events in heterogeneous populations of cells.

    Shane Buker

    Head of Lead Discovery

    Accent Therapeutics

    Currently head of lead discovery at Accent Therapeutics, where I coordinate the development of various novel biochemical assays and as well as their use in high throughput screening. Formerly at FORMA Therapeutics and Constellation Pharmaceuticals.

    Charles Lesburg

    Merck & Co. Inc.

    Charles Lesburg trained in the laboratory of David Christianson, where he studied structure-function relationships in CAII. He also kicked off a collaboration studying sesquiterpene synthases. Employed at Schering-Plough in Kenilworth NJ, he published the first structure of HCV polymerase, and contributed to many drug discovery programs. After acquisition by Merck & Co., he moved to MRL/Boston to enhance the drug discovery efforts and has been involved in many programs – mainly concerning oncology and immunology – including identification and optimization of small molecule inhibitors and agonists, as well as peptides and oligonucleotides. He remains passionate about the development and use of computational tools for the organization and dissemination of macromolecular structural information, from experiment to analysis. Since 2005, Dr. Lesburg has served on the board (Chair, 2007-2009) of the Industrial Macromolecular Crystallographic Association, dedicated to the funding and operation of a synchrotron X-ray beamline.

    Timothy Spicer, Ph.D.

    Co-Director, Scripps Molecular Screening Center

    Scripps Research-Florida

    Tim Spicer joined Scripps early on at its onset in Jupiter Florida and has been working there for 10 years. Prior to that he was employed at Bristol-Myers Squibb Co. for nine years as a Research Scientist in the Department of Lead Discovery and Profiling, Discovery Technologies and Infectious Diseases. Tim received an MS in microbiology at the SUNY Health Science Center at Syracuse. He has authored 75 publications and 4 patents. Tim works across multiple organizations and currently co-directs the Scripps Molecular Screening Center. He leads a team that implements assays and supports screening on fully automated platforms. He has experience developing anti-microbial, GPCR, kinase, protease, nuclear receptor, and/or ion channel assays in a variety of HTS-compatible formats (reporter-gene, TR-FRET, HTRF, fluorescence, luminescence, and absorbance). He is recognized at Scripps and by collaborators as a leader in evaluating new assay technologies for the purpose of making UHTS the standard.

    Oivin Guicherit, Ph.D.

    Director of Applications

    StemoniX

    Since obtaining his PhD from Baylor College of Medicine and postdoctoral training at Stanford University, Dr. Oivin Guicherit, Director of Applications at StemoniX, has invested 20+ years in developing the biopharma industry, designing, implementing, and managing drug discovery efforts. Over the years he has cultivated extensive knowledge and expertise in applying chemical and oligonucleotide tools to cell-based (2D/3D/co-culture) and organotypic platforms for target-identification and validation, screening and lead optimization, and MOA dissection. Before joining StemoniX, Dr. Guicherit worked in development at Janssen Pharmaceuticals, Regulus Therapeutics, Pfizer Global R&D, and ChemDiv.

    Paul Johnston, Ph.D.

    University of Pittsburgh Dept. Pharmaceutical Sci.

    Dr. Johnston obtained a B.Sc. with Honors (2.1) (1978) and a Ph.D. (1983) in Biochemistry, from the University of East Anglia, Norwich, England. Postdoctoral positions at the University of North Carolina, Duke University, and the University of Texas Southwestern Howard Hughes Institute provided diverse experience in biochemistry, molecular biology, cell biology, immunology, protein purification and recombinant protein expression. Dr Johnston has twenty-nine years of drug discovery experience in the Pharmaceutical, Biotechnology, and Academic sectors. He is an innovator of cell based lead generation, and founding member of the Society for Biomolecular Imaging and Informatics. In 2005, he joined the University of Pittsburgh to design and build the Pittsburgh Molecular Library Screening Center where he led 21 HTS campaigns and the NCI 60 drug combination screen. In 2011, he established independent chemical biology laboratories to discover new drugs or drug combinations for prostate cancer, melanoma, and head and neck cancers.

    Marie Schwinn, Ph.D.

    Advanced Technologies Group

    Promega Corporation

    Dr. Schwinn is a member of the cell biology team within the Advanced Technologies Group at Promega where she has helped develop luciferase-based technologies for studying intracellular protein interactions, abundance, and post-translational modifications. Most recently, she has focused on combining these technologies with CRISPR/Cas9 to study protein dynamics at the endogenous level. Prior to joining Promega, Dr. Schwinn earned her doctorate in Biochemistry from the University of Wisconsin-Madison in the lab of Dr. Hector F. DeLuca, and she received post-doctoral training from Dr. Donna M. Peters in the Department of Pathology and Laboratory Medicine.

    Sapna Desai

    Biological Investigator

    GlaxoSmithKline

    Sapna Desai is a Biological Investigator within the Screening, Profiling and Mechanistic Biology group at GlaxoSmithKline. Her focus is using molecular and cellular biology techniques to design, build and execute complex and recombinant cellular screening assays supporting a variety of therapeutic areas across preclinical drug discovery. Prior to joining GlaxoSmithKline in 2004 she completed her BSc in Molecular Biology from the University of Hertfordshire.

    Kristin Riching, Ph.D.

    Senior Scientist

    Promega Corporation

    Kristin received her PhD in Biomedical Engineering from the University of Wisconsin – Madison, where she studied the structural and mechanical properties of collagen fibers and their effects on breast cancer cell migration in invasive ductal carcinoma. She joined Promega in 2014 as a postdoctoral researcher and is currently a Senior Scientist developing technologies to characterize degradation and protein interactions within the ubiquitin proteasomal pathway in living cells.

    Feng Liang, Ph.D.

    Group Leader

    Cystic Fibrosis Foundation

    Feng Liang is a skilled biologist with pharmaceutical experience and a successful track record in target validation, assay development, screening, and SAR. He received B.S. (Biochemistry) at Peking University and Ph.D. (Molecular Biology) at Cornell University. Experienced in both pharmaceuticals and start-up biotech, Feng is current a group leader in CF Foundation Lab.

    Pavan Chandra Konda, Ph.D.

    Duke University

    I am currently a postdoctoral researcher in the computational optics lab at the Duke university led by Dr. Roarke Horstmeyer. Before my current position, I worked as a postdoctoral researcher in the school of physics and astronomy at the university of Glasgow, where I have also conducted my PhD research. I received my bachelor’s degree in Engineering Physics from the Indian Institute of Technology Guwahati.

    My current research interests are in the areas of computational imaging, novel microscopy methods, low-cost microscopy, high-speed gigapixel imaging, micro-endoscopy and in vivo imaging. Other areas of expertise include multi-spectral imaging, extended depth-of-field imaging, compressive sensing and imaging using speckle.

    Thierry Dorval, Ph.D.

    Head of Data Science Lab

    Servier

    Thierry Dorval received a B.S. degree in physic and graduated in image processing and artificial intelligence at Pierre & Marie Curie University, Paris, France. He received a Ph.D.d then joined the Institut Pasteur Korea in 2005 first as researcher in biological image analysis then as a group leader specialized in High Content Screening applied to cellular differentiation as well as toxicity prediction.

    In 2012 he joined AstraZeneca, UK. His activities were about developing and advising on quantitative image and data analysis solutions in support of high content phenotypic screens in addition to cellular and tissue imaging.

    In 2015 he joined Servier, France, as leader of the High Content Screening group within CPCB CentEX. He is currently still working on phenotypic approaches to improve drug discovery pipeline using high content strategies and currently lead the Data Science Lab.

    Lynn Rasmussen, B.S., M.S.

    Associate Director

    Southern Research

    Lynn Rasmussen holds a B.S. in both Chemistry and Biology from Virginia Tech and a M.S. in Biomedical Sciences from Hood College. She has worked on Rickettsia at the University of Maryland, emerging infectious diseases at USAMRIID and Lentiviruses at the Frederick Cancer Research and Development Center. She served as coordinator for the DNA Sequencing Core facility at the FCRDC where she designed automation systems to handle the increasing throughput requirements of the Core. She is now Associate Director of the Southern Research HTS Center where she has overseen the screening of a wide range of HTS campaigns. These include infectious disease, cancer and obesity targets. She designed the automation platforms currently in use at the Southern Research HTS Center, including one housed in a bio-containment enclosure for infectious disease work

    Shushant Jain

    Group Leader

    Charles River

    Shushant Jain is currently a group leader at Charles River where he utilizes high throughput – high content methodology for target identification, target validation, lead identification, and lead optimization in physiologically relevant cellular model systems such as primary or stem cells. Prior to Charles River, he was the lead developer of phenotypic assays to enable discovery of novel pathways or targets in numerous neurodegenerative diseases as well aid in the understanding the role of common genetic variation in disease pathogenesis.

    Paul Harper

    Principal Scientist

    AstraZenec

    Paul Harper is a Principal Scientist within the Global High Throughput Screening (HTS) Centre at AstraZeneca. Over the past two decades he has held positions at GlaxoSmithKline, Pfizer and AstraZeneca, during which he has undertaken cellular and biochemical assay development, small molecule screening and an ever-increasing focus on new technology, automation and facility development. Since 1999 within AstraZeneca Paul has successfully deployed over 15 large scale automation projects, across a variety of research functions with multiple integration vendors. In his current role Paul is tasked to design the UK Centre for Lead Discovery, creating the next generation of automated screening technology for AstraZeneca’s upcoming Cambridge research facility.

    James Beck

    Eli Lilly

    Mitchell Hull

    Calibr at Scripps Research

    Mitch began his screening career in 1997 at Tularik Inc. Here, he worked in assay development and championed the company’s move from 96 to 384 well assays. He left Tularik in 2001 to pursue a short career in web development. Returning to biotech and in 2005, he joined the Advanced Automation Technologies group at the Genomics Institute of the Novartis Research Foundation (GNF). Here, in addition to screening, he worked with project teams to integrate large uHTS systems, profiling systems and an automated protein production platform. He left GNF in 2012 to join the California Institute for Biomedical Research (Calibr) and to lead it’s HTS group. In addition to HTS, he has built and maintained customized Laboratory Information Management Systems (LIMS) for compound management and screening.

    David Dambman

    Director of Software Development

    Biosero, Inc.

    avid Dambman, Director of Software Development for Biosero has devoted his time, knowledge and efforts into software and engineering development for the company over the past 5 years. As a lifelong engineer and programmer, David has implemented his vast knowledge and capabilities into the development and integration of Biosero's Green Button Go scheduling software. Under his direction, Biosero has developed an easy and intuitive software for users that has the capability of controlling simple to complex workstations using the most advanced software technology available. David's vast knowledge and programming capabilities have assisted customers in customizing the runtime environment within their lab as well as improving their throughput efficiency and accuracy.

    Silvio Di Castro, M.Sc.

    AstraZeneca

    A chemical engineer by training, Silvio joined Compound Management at AstraZeneca in 2002. During the time at AZ, Silvio has developed a deep expertise in laboratory automation, from programming simple benchtop units to developing large automated platforms for high-throughput screening. Working across functions and countries, Silvio has developed a large network of strong connections, and implemented solutions for automated sample handling in several areas of the business.

    In his current role  as associate principal scientist, Silvio is leading the deployment of the first fully acoustic Sample Management system in the world, developed by AZ in a collaborative
    partnership with Labcyte and Brooks. He is also aligned with global initiatives to improve sample storage, handling and usage of new therapeutic modalities (peptides, RNAs, DNAs and more).

    Prior to joining AstraZeneca, Silvio gained an MSc in Chemical Engineering at the "Federico II" University, Naples (Italy), under the supervision of Prof. Guido Greco.

    Adam Corrigan

    Image Analytics team in Discovery Sciences

    AstraZeneca

    I currently work in the Image Analytics team in Discovery Sciences at AstraZeneca. Since joining AZ three years ago, the field of image analysis has been transformed by the explosion of machine learning and AI methods, and I have fortunate enough to develop and apply these cutting edge techniques to explore and shape the future of cellular screening and imaging.

    Prior to joining AstraZeneca I worked in academia developing quantitative microscopy methods to solve a range of biological problems, including gene expression, cell division, and amyloid plaque formation.

    Mahnaz Maddah

    Dana Solutions

    Dana Solutions LLC

    Mahnaz is a Managing Member of Dana Solutions, and has 16+ years of experience in artificial intelligent algorithms for products in life sciences. She is an inventor of multiple products including an AI-based cell counting software for an infertility medical device, an AI-based phenotypic drug screening platform, and a structural toxicity testing platform that is the basis of a current research collaboration with the FDA. As a co-founder and CTO of Cellogy, she led the technical development of Pulse, the first computer vision system for video-based characterization of stem cell-derived cardiomyocytes. She has been co-PI on an NIH Phase-II SBIR that supported the development of Pulse. As a lead scientist at Auxogyn, GE Research, and SRI, she developed novel algorithms for different applications. She received her master's degree from Univ. of Tehran and her PhD in Electrical Engineering and Computer Science from MIT, Computer Science and Artificial Intelligence Lab (CSAIL).

    Avtar Singh

    The Broad Institute

    Postdoctoral associate at the Broad Institute of Harvard and MIT working in the lab of Paul Blainey.

    Gregory Vladimer, Ph.D.

    CSO

    Allcyte

    Gregory Vladimer is the CSO of Allcyte, a startup in Vienna, Austria. He received his PhD from UMass Medical School where he studied inflammation, and was a Senior Postdoctoral Fellow at CeMM in Vienna. Together with the Department of Hematology of the MedUniWien, spearheaded the use of single-cell image-based screening for the personalized identification of treatments for hematological cancers through a prospective clinical trial, and several retrospective studies. His work is published in journals including Nature, Lancet-Hematology, NEJM, and Cell, and he is on the steering-committee for the precision haematology working group of EHA advocating for standards around functional testing.

    Jonathan Wingfield

    AstraZeneca

    Joined AZ in 2000, as part of a team responsible for delivering automation solutions and technology into the disease area teams post high-throughput screening. Was invited to establish a Lead Generation Automation team within Oncology and this evolved into a centralised biochemical screening team in 2006. The centralised team utilized leading edge technology to deliver high quality data to global projects, this included delivery of acoustic droplet ejection technology. In 2008 the team won the Microsoft Innovation in Pharma Award for deployment of a LIMS system. In my current science role, I remain interested in landing technologies that can add value to our core business, one such example is the acoustic mass spectrometry collaboration between Labcyte and AZ. This project won the SLAS Innovation award (2015) and has generated a significant amount of external interest.

    Jeffrey Gross

    GlaxoSmithKline

    Laura Riva, Ph.D.

    Sanford Burnham Prebys Medical Discovery

    Laura graduated and got a Master in Molecular Biology from the University of Padova (Italy) in 2009. She received her PhD in virology from the University of Liege (Belgium) in 2013, with a thesis on the tegument protein ORF9p of the Varicella Zoster virus (VZV). She then moved to France for a postdoctoral opportunity at the Pasteur Institute of Lille. During her training, she worked on the Hepatitis C virus (HCV) with a focus on the entry and replication of the virus, becoming familiar with high-content and small chemical compound screening.

    She joined the SBP Medical Discovery Institute in 2017 as a postdoctoral associate. Her current main focus is the identification and development of antivirals targeting emergent RNA viruses, including Flaviviruses and ebolavirus, through high-throughput screening approaches.

    Steven van Helden

    Pivot Park Screening Centre

    Steven van Helden studied chemistry at Utrecht University and, after obtaining his Ph.D. , worked in various roles in pharmaceutical industry for 20 years. Since 2003 he has been responsible for High Throughput Screening (HTS) operations and strategy at Organon/MSD. After the closure of those research facilities he developed a business plan for continuation of the screening activities in Oss, The Netherlands. This led to the formation of the Pivot Park Screening Centre (PPSC) and a central role of this company in the European Lead Factory. Steven is now Chief Technology Officer at PPSC.

    Pierre Baillargeon

    The Scripps Research Institute

    Senior Robotics Engineer

    Pierre is currently the Senior Robotics Engineer within the Lead Identification lab at Scripps Research where he supports Compound Management, High Throughput Screening, Assay Development and Informatics efforts by developing, assembling and integrating novel automated hardware and software. Pierre has worked at Scripps Research since the establishment of the lab in 2005. The Lead Identification lab at Scripps is responsible for supporting both industrial and academic drug discovery efforts with a proprietary >600,000 sample library and the NIH's >300,000 sample MLPCN collection.

    Over the past decade at Scripps, Pierre has lead engineering efforts on several novel laboratory instruments including the Plate Auditor microplate inspection platform and most recently the Microplate Assistive Pipetting Light Emitter.

    Peter Bajcsy

    NIST National Institute of Standards and Technology

    Rob Howes, Ph.D.

    AstraZeneca

    Rob completed his PhD at the MRC Laboratory of Molecular Biology understanding EGFR signalling pathways in Drosophila followed by post-doctoral positions at Stanford University, USA and Cambridge University. In 2001 he joined Vernalis, a UK-based drug development company where he was in charge of the Screening group working across several disease areas including Oncology and Neuroscience.

    In 2008 he helped start Horizon Discovery, a translational genomics company that uses the adeno-associated virus (AAV) and other gene targeting technologies such as CRISPR, to generate isogenic human cell lines. At Horizon he also established their Centres of Excellence program to enable academic groups with the gene targeting technologies which included such groups as the National Institutes of Health, Cambridge
    University and Yale University. 

    In 2013 he joined MedImmune, the global biologics division of AstraZeneca, leading the High Throughput Screening team based in Cambridge, UK. 

    Markus Muellner, Ph.D.

    Chief Technology Officer

    PhoreMost

    Markus is the Chief Technology Officer at PhoreMost, a Cambridge UK Biotech with a novel target discovery platform to drug previously undruggable targets. Markus has a background in engineering, IT and Life sciences. He has a PhD from the Medical University of Vienna (Medical Chemistry) that was followed by a postdoc at the Center for Molecular Medicine (CeMM) where he established a functional genetics platform that led to the discovery of novel cancer vulnerabilities. He joined PhoreMost in 2015, set up the SITESEEKER technology platform and is heading the R&D and bioinformatics teams.

    Gregory Alberts, Ph.D.

    Global Subject Matter Expert

    Lonza Inc.

    Dr. Gregory Alberts is currently the Global Subject Matter Expert for Lonza, and has worked at Lonza (and previously Amaxa) since 2003, and has considerable experience in Nucleofection, primary cells (including stem cells and iPSC generation), and endotoxin testing solutions, and is well versed in the use of CRISPR and other genome-editing technologies with Nucleofection. He received a Ph.D. from the George Washington University in Molecular Biology, and an M.S. in Bacterial Genetics from UIC.

    David Gilham

    Celyad

    Thomas Miller

    Institut Paoli Calmettes

    Exploring the druggability of CD47 signaling using small molecules and novel discovery methodologies. Focused on the development of "second-generation" CD47 inhibitors for anti-tumor immunotherapy. Principal Investigator with expertise in assay development, high-throughput screening, structure-based drug development, tumor immunobiology, public and private fundraising, and international team leadership.

    Torben Gjetting

    Symphogen

    Aram Chung, Ph.D.

    Korea University

    Dr. Aram Chung is an Associate Professor of Biomedical Engineering Department at Korea University (KU), and directs the Biomicrofluidics laboratory. He joined KU in 2017 from Rensselaer Polytechnic Institute (RPI) in Troy, NY, USA where he was an Assistant Professor of Mechanical Engineering Department (2013-2017). Before RPI, he conducted postdoctoral studies (2011-2013) in Bioengineering at the University of California, Los Angeles (UCLA). He received his M.S. (2009) and Ph.D. (2011) in Mechanical Engineering from Cornell University and a B.S. (2006) in Mechanical Engineering from Seoul National University (SNU). Among other honors/recognitions, he was awarded the Early Career Award from the BioChip Society, the Seok-Top Teaching Award, the KSEA Young Investigator Award, the Class of 1951 Outstanding Teaching Award, the UCLA Chancellor's Award for Postdoctoral Research, the Grand and the 1st Poster Prizes at ASME-IMECE, the Samsung Humantech Paper Silver Award, and the Best Poster Award from the CNF Symposium.

    Joseph de Rutte

    University of California, Los Angeles

    Graduate Student Researcher in the Di Carlo Lab working on microparticle-based technologies for next generation diagnostics and therapeutics.

    Raehyun Kim

    University of North Carolina at Chapel Hill

    Nicholas Geisse

    Chief Science Officer

    NanoSurface Biomedical

    Nick Geisse is the Chief Science Officer at NanoSurface Biomedical, a spin-out company from the University of Washington Bioengineering department in Seattle. Nick graduated from Boston University with a B.A., Biochemistry and Molecular Biology. He completed his graduate studies (Ph.D.) in Pharmacology at Cambridge University in England under Dr. RM Henderson, followed by a postdoctoral fellowship in cardiac cell and tissue engineering at the Harvard University School of Engineering and Applied Sciences under Prof. Kevin Kit Parker. After his postdoc, Nick went into industry and worked for Asylum Research (a manufacturer of Atomic Force Microscopes) as a scientist and project manager. At NanoSurface, Nick is part of the executive management team and is specifically tasked with guiding the overall scientific strategy of the company in addition to developing and bringing to market NanoSurface’s next-generation of innovative products aimed at increasing the predictive power of in vitro cell based assays.

    Scott Magness

    UNC Chapel Hill

    Lisa Mohamet, Ph.D.

    GSK

    Lisa obtained her PhD in cell biology from The University of Manchester in 2006 and has over a decade of experience in human stem cell biology in both academia and industry. She is an Enterprise Fellow of the Royal Society of Edinburgh/BBSRC and is co-founder of a spin-out company, StrataStem Ltd. Lisa was named as one of the Biobeat 2016 ‘rising stars’ of the top 50 UK women entrepreneurs and leaders in Biobusiness. In 2017, Lisa joined GSK in preclinical R&D to head up the advanced cellular model platform group (including iPSC and 3D models) to support target validation and lead drug discovery programs. More recently, she moved to the newly formed Functional Genomics department to lead large-scale CRISPR screening platforms for novel target ID. Lisa has passion for the application of novel technologies to support the translation of scientific discoveries into potential therapeutics.

    Richard Cheng, B.Sc., M.A.Sc.

    University of Toronto

    Samuel Berryman

    University of British Columbia

    Samuel Berryman is a master’s student in the Multi-Scale Design lab under the supervision of Dr. Hongshen Ma and is a recipient of a graduate award funded by the Centre for Blood Research. Samuel’s research focuses on developing new assays for cellular informatic and micro-scale automation. His work involves utilizing deep-learning for the identification and segmentation of cellular phenotypes in fluorescent microscopy images. Samuel is also working on integrating these informatic approaches with microscope automation for single-cell isolation, separation and sequencing.

    Lauren DeMeuse

    Roam Analytics

    Viral Vyas, MSIS

    Lead IT Business Partner Translational Medicine

    Bristol Myers Squibb

    Viral Vyas is a Lead IT Business Partner at Bristol Myers Squibb responsible for leading teams that deliver informatics capabilities to broad range of scientific stakeholders in the Translational Medicine organization. He received his undergraduate education in Microbiology and Masters in Information Management. Viral Joined Bristol Myers Squibb in 2000 as an Associate Research Scientist in DMPK group and transitioned into R&D IT in 2004. Viral has worked on numerous informatics initiatives that streamlined laboratory workflows. He is passionate about creating informatics strategies that allow scientists to focus on creating scientific knowledge rather than manually assembling and reporting data.

    Patrick Cullen

    Yahara Software

    James Smagala

    Revolutionary Informatics

    Umesh Katpally

    Director - Data Advisory for Data Sciences

    BC Platforms

    Umesh Katpally is currently Director - Data Advisory for Data Sciences at BC Platforms. Previously, he worked at Novartis focusing on research informatics and before that he worked at various bio-pharma companies and academic institutions focusing on viral vaccines research. He is interested in enabling innovation with the use of new and evolving technologies that fall under the Lab of the Future umbrella. In his current role at BC platforms he supports potential and current Data Science customers with advising on the strategy needed to answer their research questions, inclusive of data sources and data points. This is to help with integrating and mining clinical phenotypic data combined with genotypic profiling data sets from various data sources to augment drug development pipeline. BC Platforms is a world leader in providing powerful genomic data management and analysis solutions to address some of the biggest healthcare challenges today by leveraging the convergence of genomics and healthcare information technologies.

    Christoph Otto

    TU Dresden

    Christoph Otto studied Bioprocess Engineering at the TU Dresden, Germany and graduated in 2015. Since then he is a PhD student in the SmartLab-systems research group at the Chair of Bioprocess Engineering. He investigates the logistics in current laboratory environments and designs solutions towards automation and higher troughput in the field of laboratory automation and automated sample treatments focusing on samples in culture dish environments.

    Guru Singh

    LabTwin

    Guru joins LabTwin with several years of experience as a biotech researcher and a lifetime’s worth of passion for entrepreneurship. Beginning his journey as a biotech engineer in India, he published numerous research papers and co-founded life science startups and foundations. After earning his Professional Science Master’s in Biotechnology from the University of Delaware, Guru served as a marketing leader at two California-based life science SaaS startups.

    Michael Shanler

    Gartner, Inc.

    Michael Shanler advises CIOs and IT leaders on industry technologies and trends impacting the life science and healthcare industry. Prior to Gartner, Michael worked at BD Biosciences, where he developed scientific and analytical products. He holds several patents for life science products used by researchers across the globe, today. He also worked at Genetics Institute in Cambridge, MA, and specialized in laboratory automation and laboratory informatics. He is a biomedical engineer by training (Boston University) and lived on four continents as a child. He lives with his lovely wife and three children in Sudbury, MA USA, is an avid skier, home head chef, guitarist, and race car-junkie.

    Oren Kraus, BASc, MASc, Ph.D.

    Cofounder CTO

    Phenomic AI

    Oren Kraus co-founded Phenomic AI after completing his Ph.D. in Dr. Brendan Frey's lab at the University of Toronto. His research focused on applying deep learning to high-throughput microscopy screens used in drug discovery and cell biology research. Together with Jimmy Ba and collaborators at the Donnelly Centre for Cellular and Biomolecular Research (CCBR), Oren was one of the first to publish the application of deep learning to microscopy data. Oren founded Phenomic AI with the goal of accelerating the interpretation of phenotypes in bio-medical images with machine learning for applications in drug discovery and cellular diagnostics.

    Laurence Arnold

    Pelago Bioscience

    Drug discovery scientist with interests in assay development and target engagement studies. A Background of biophysics and biochemistry within the drug discovery field.

    Kirsten Tschapalda

    AstraZeneca

    I have a strong interest in cell based high throughput screening (HTS) technologies. Over the years I have worked in both academic and industry HTS campaigns. I started screening during my PhD at the Max-Planck Institute in Dortmund and specialized further during my postdoctoral time at the Karolinska Institute/Scilifelab in Stockholm. Since 2017 I am employed as a senior research scientist in the Global High Throughput Screening Centre at AstraZeneca. Here, I am delivering to both internal and external HTS projects and explore the use of different CETSA technologies in high throughput.

    Matthew Robers

    Promega

    Matthew Robers is a Senior Research Scientist and Group Leader at Promega Corporation. Following his post-graduate training at University of Wisconsin-Madison, Matthew has authored nearly 40 peer-reviewed publications and published patents on the application of novel assay chemistries to measure intracellular protein dynamics. Matthew's team currently focuses on the development of new technologies to assess target engagement, and has developed a biophysical techniques for quantifying compound affinity and engagement kinetics at selected targets within intact cells.

    Matthew Disney, Ph.D.

    Professor

    Scripps Research

    Matt Disney is a Professor in the Department of Chemistry at Scripps Research. His laboratory works on small molecule targeting of RNA and seeks to answer fundamental questions on molecular recognition between RNA and small molecules to study problems of biomedical importance. The group developed a strategies to: (i) design structure-specific small molecules from the RNA’s sequence; (ii) synthesize drugs on-site in disease-affected cells to affect their function and to image them; (iii) study the biology of coding and non-coding RNAs, with a focus on incurable rare diseases and difficult-to-treat cancers; and (iv) interface RNAs with quality control machinery using small molecules and chimeras thereof to eliminate them from cells and animal models of disease. The lab’s research has garnered various awards including the Sackler Prize, Barry Cohen Award in Medicinal Chemistry, NIH Director’s Pioneer Award, the Tetrahedron Young Investigator Award, the Eli Lily Award in Biological Chemistry, and others.

    Jay Schneekloth

    NIH

    Robert Blake, DPhil

    Genentech

    Robert A. Blake (DPhil) is a scientist in drug and target discovery specializing in oncology drug development, cellular and biochemical assays for high throughput screening, automated fluorescence imaging, signal transduction and protein degradation. He is currently a scientist in the department of Biochemical and Cellular Pharmacology at Genentech and worked previously at Sugen, Exelixis, and iPierian. He has published on the discovery of various types of drugs including: novel selective kinase inhibitors, HSP90 inhibitors and estrogen receptor degraders. His current focus is the development of drugs whose mechanism of action includes the degradation of the target protein.

    Emery Smith

    Scientific Associate

    Scripps Research Institute Florida

    Emery Smith is an Scientific Associate at the Scripps Research Institute Molecular Screening Center located in Jupiter, FL, USA. Since joining the group in 2010, Emery has interacted both with corporate and academic partners to implement miniaturized, ultra-high-throughput screens of collections of up to 1 million compounds. The screens have been focused around GPCRs. Prior to joining the group in 2010, Emery was working with Dr. Charles Weissmann at Scripps working on Prion disease. This work started in 2006. Prior to 2006, Emery began his research career as a Research Associate at Athersys Inc. located in Cleveland, OH, USA. There he worked in both the VT (validated targets) group and the Regenerative Medicine group. The focus of this work was in the isolation and validation of adult human stem cells, currently known as Multistem.

    Delphine Collin, Ph.D.

    Cedilla Therapeutics

    Delphine Collin joins Cedilla from HarkerBIO, where she served as their chief innovation officer. Prior to HarkerBIO, she served as senior principal scientist at Boehringer Ingelheim (BI) and led a biophysics group focused on lead identification and optimization in the small molecule drug discovery group. While at BI, Delphine also started her own consulting firm, Delphine Collin Consulting, LLC., where she supported companies with specialized biophysical approaches to drug discovery. Prior to BI, Delphine was a research fellow at Merck & Co. Delphine holds a Ph.D. in biophysical chemistry and doctorate in pharmaceutical sciences from the University of Paris XI, France.

    Maciej Grajewski

    SG Papertronics B.V. and University of Groningen

    Maciej Grajewski studied Biotechnology at Poznań University of Life Sciences. After graduation, he moved to Groningen for his PhD studies on microfluidic cell cultures and optical real-time cell monitoring. This work was performed with professor Verpoorte, in the Pharmaceutical Analysis group. It was also part of a larger EU collaborative network (LiPhos), which aimed to design, develop and test an optical tool for endothelial cell behaviour. Currently, Maciej’s interests revolve around real-time monitoring systems for diagnostic and environmental purposes.

    Brian Musselman

    ​CEO and CSO

    IonSense, Inc.

    CEO and CSO of IonSense which produces ambient ionization sources and automation devices for mass spectrometry SciMarket Strategies, Inc. President of primary marketing business for instrumentation startups Marketing Director for MALDI technology, Applied BioSystems Director of Michigan State University / NIH Mass Spectrometry Resource Facility PhD Biochemistry, Michigan State Univ., BS Chemistry, University of Connecticut

    Daniel Austin, Ph.D.

    Professor of Chemistry

    Brigham Young University

    Daniel Austin is a Professor of Chemistry at Brigham Young University, Provo, Utah. He received a PhD from the California Institute of Technology and has also worked at Sandia National Laboratories. His research focuses on chemical processes in high-velocity impacts relevant to the space environment, and also in development of miniaturized mass spectrometers for portable and field applications.

    J. Michael Ramsey

    Minnie N. Goldby Distinguished Professor of Chemistry Chair

    UNC Chapel Hill

    J. Michael Ramsey holds the Minnie N. Goldby Distinguished Professor of Chemistry Chair at the UNC - Chapel Hill. He is also on the faculty of the Departments of Biomedical Engineering and Applied Physical Sciences. He is a member of the National Academy of Engineering and a Fellow of the Optical Society of America, the American Chemical Society, and the American Institute for Medical and Biological Engineering. Moreover, Dr. Ramsey is the scientific founder of Caliper Technologies (NASDAQ:CALP), renamed Caliper Life Sciences and acquired by PerkinElmer in 2011. He is also the scientific founder of the venture-backed companies 908 Devices Inc., a company developing revolutionary compact mass spectrometry and chemical separations-based products, and Genturi Inc., a genomics tools provider. Prof. Ramsey has published over 300 peer-reviewed papers (H-index = 64) and presented over 500 invited, plenary, or named lectures. In addition, he has over 150 issued and 20 pending patents.

    Pak Kin Wong

    Professor of Biomedical Engineering, Mechanical Engineering, and Surgery

    The Pennsylvania State University

    Dr. Pak Kin Wong is a Professor of Biomedical Engineering, Mechanical Engineering, and Surgery at the Pennsylvania State University. Dr. Wong’s research focuses on biomimetic materials and systems for elucidating collective cell migration in tissue regeneration and cancer metastasis, and developing molecular diagnostic systems. He has published over 100 peer-reviewed journal articles across multiple disciplines, including Proceedings of National Academy of Sciences, Nature Communications, ACS Nano, and Advanced Materials. Among other honors, Dr. Wong was awarded the NIH Director's New Innovator Award in 2010, Arizona Engineering Faculty Fellow in 2011, AAFSAA outstanding Faculty Award in 2013, and SLAS Tech 10 – A Top 10 Breakthrough in Innovation in 2015. Dr. Wong is elected as a Fellow of the Royal Society of Chemistry, American Institute for Medical and Biological Engineering, and Society for Laboratory Automation and Screening for his contributions in biomedical engineering and nanomedicine.

    Georges Muller, Ph.D.

    SEED Biosciences SA

    Dr. Georges Muller is the CEO and cofounder of SEED Biosciences SA, a spin-off from Ecole Polytechnique Federale de Lausanne (EPFL), developing and commercializing enabling technologies for personalized medicine at a single cell resolution. He is co-inventor of SEED Biosciences’ core technology called DispenCell and co-authored several patents. He is the recipient of multiple awards for young entrepreneurs, including the Venture Leaders Prize in 2017 (given to top Swiss entrepreneurs) as well as the Ignite Award at SLAS2019, Washington, DC. Georges holds a masters and a Ph.D. in bioengineering from EPFL.

    John Griffin, Ph.D.

    Integral Health

    John Griffin is Chief Scientific Officer at Numerate, which has developed and applies an AI-driven approach to small molecule drug design. He was formerly Co-Founder and Chief Scientific Officer of Theravance and Assistant Professor of Chemistry at Stanford University. John is the author of 39 publications, an inventor of 27 issued patents, and the recipient of awards including a Cope Scholar Award from the ACS and a Dean's Award for Teaching from Stanford. He was recently elected a Fellow of the American Association for the Advancement of Science. John received a B.S. in Chemistry from Hope College, a Ph.D. in Chemistry from Caltech and was a Postdoctoral Fellow at Harvard Medical School.

    Carleen Klumpp-Thomas

    NIH/NCATS

    Carleen, an expert in automation engineering by profession, earned her B.S. degree in Bioengineering from Syracuse University and her M.S. in Biomedical Engineering from NYU Polytechnic School of Engineering. Prior to joining NCATS, Carleen has been has been with NCATS for 14 years.

    Carleen manages and runs all of the automated screening platforms for their Research Services Core (RSC). RSC's multi-disciplinary research technologies enables the ongoing operation of all of NCATS’ research activities. These automated platforms perform a wide variety of experiment types ranging from biochemical, cell based, RNAi and other existing and novel assay technologies. The advanced instrumentation, laboratory techniques, protocols and methods necessary to keep NCATS at the leading edge of scientific research require staying up to date with new and emerging technologies, and in constant communication with all researchers. This comes naturally to Carleen and no detail is too small for her to overlook.

    Raphael Franzini, Ph.D.

    University of Utah

    Raphael Franzini received his M.Sc. in chemistry from EPFL and his Ph.D. in organic chemistry from Stanford University under the guidance of Prof.Eric Kool. In 2012, he joined the group of Prof. Dario Neri at ETHZ as a VPFW-ETH postdoctoral fellow. Since 2015, he has been an Assistant Professor in the Department of Medicinal Chemistry at the University of Utah. His research interests involve the development of bioorthogonal chemistry for applications in chemical biology and drug delivery and the advancement of DNA-encoded chemical libraries for the discovery of drug hit compounds and chemical probes.

    Michael Kossenjans, Ph.D.

    Principal Scientist

    AstraZeneca

    Michael Kossenjans is a Principal Scientist within the Discovery Sciences unit at AstraZeneca Gothenburg, Sweden. He is currently leading a group of scientists focussing on the implementation of automation in early phase drug discovery.

    Michael has been working with AstraZeneca since 2004. Before joining the Discovery Sciences unit in 2012 he occupied various roles in the Medicinal Chemistry department of the cardiovascular, renal and metabolic disease research area. Michael has been key in the discovery of a novel treatment of diabetic nephropathy and played a significant role in the build-up of AstraZeneca’s small molecule screening collection, among others through innovative compound exchange programs with peers.

    Michael holds a PhD in organic chemistry and performed research in academic labs in Germany, Spain and the US before starting his industrial career at Sanofi in 2000.

    David Lancia

    FORMA Therapeutics

    Jarrod Walsh

    AstraZeneca

    Jarrod graduated in 2000 from the University of Liverpool with a degree in Genetics and joined the High Throughput Screening (HTS) department of AstraZeneca in 2001. His current role is Associate Principal Scientist within the Hit Discovery department that forms part of AstraZeneca’s Discovery Sciences function. During his 18 years in company Jarrod has worked extensively with screening applications, assay development activities and biophysical technologies. Since 2012 Jarrod has focused on devising approaches to identify and eliminate compounds that function via undesirable mechanisms of action to improve the quality of hit to lead compounds. His work interests include the application of biophysical techniques and development of new technologies to improve drug discovery screening and hit identification activities.

    Kelly Frazer

    University of California, San Diego

    Dr. Frazer is an internationally renowned leader in the field of genome biology. She is the director of UC San Diego Institute for Genomic Medicine and is a professor and founding chief of the Division of Genome Information Sciences in the Department of Pediatrics at UC San Diego. Over the past seven years, Dr. Frazer’s lab has systematically derived and characterized a unique collection of iPSC lines from 222 individuals – referred to as iPSCORE (iPSC Collection for Omic Research). The iPSCORE resource is currently being used to conduct genotype – molecular phenotype correlations in both pluripotent stem cells and iPSC-derived cell types. We recently established that iPSC-derived cardiovascular progenitor cells (CVPCs) are fetal-like, and are leveraging this model system to identify and characterize developmental genetic factors which affect cardiovascular disease later in life by acting in specific fetal cardiac cell types.

    Witold Postek

    Institute of Physical Chemistry of the Polish Academy of Sciences

    Witold Postek graduated from Warsaw University of Life Sciences in 2012 as BSc and in 2014 as Msc in Biotechnology. Later he joined the group of Piotr Garstecki at the Institute of Physical Chemistry of the Polish Academy of Sciences, where he has been working on microfluidic droplet-based systems for automation and miniaturization of biochemical and microbiological assays. Witold had worked in a number of labs, including those in Wageningen UR and TU Delft in NL, EPFL in CH, TU Dresden in DE, University of Cambridge in UK.

    Evangelos Kiskinis, Ph.D.

    Assistant Professor of Neurology and Physiology

    Northwestern University - Feinberg School of Medicine

    Evangelos Kiskinis is an Assistant Professor of Neurology and Physiology at the Northwestern University Feinberg School of Medicine. He earned a degree in Molecular Biology from the University of Surrey, a PhD from Imperial College London and trained as a postdoctoral fellow at Harvard University. His laboratory harnesses the power of human pluripotent stem cells to study neuronal development as well as to understand how neuronal function is impaired as a result of injury or disease. The overarching goal of his research is to identify points of targeted and effective therapeutic intervention for epilepsy and ALS. At Northwestern Evangelos also serves as the Scientific Director of the Stem Cell Core Facility and the Co-Director of the Stem Cell and Regenerative Biology Initiative.

    Kevin Eggan, Ph.D.

    Professor in the Department of Stem Cell and Regenerative Biology

    Harvard University

    Kevin Eggan is currently a Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, a principal investigator at the Harvard Stem Cell Institute and an Institute member at the Broad Institute’s Stanley Center for Psychiatric Research. As a young investigator in the burgeoning field of stem cell biology, Dr. Eggan garnered international recognition for his seminal work and a number of high profile awards for his creativity and productivity, including the MacArthur Foundation “Genius Grant” in 2006. In 2009, he was selected as one of 50 Howard Hughes Medical Institute (HHMI) Early Career Scientists who received six years of dedicated support to conduct transformative research. His current research applies stem cell technologies to study the mechanisms through which genetic variants confer risk for psychiatric and neurodegenerative diseases.

    In 1996, Dr. Eggan received his bachelor’s degree in microbiology from the University of Illinois. He completed a two-year predoctoral fellowship at the National Institutes of Health, before pursuing his doctoral studies in biology at The Massachusetts Institute of Technology. There he actively pursued projects focused on cloning, stem cells, and reprogramming after nuclear transfer under the guidance of genetics pioneer Rudolf Jaenisch. After completing his doctoral studies in 2002, Eggan stayed in Jaenisch’s lab for one year of postdoctoral collaboration with Richard Axel from Columbia University. In 2003, he moved to Harvard University as an independent Junior Fellow and then became an Assistant Professor of Molecular and Cellular Biology in 2005. In 2013 he was promoted to the Rank of Full Professor in the Department of Stem Cell and Regenerative Biology, the first Harvard academic department to span the Medical School and School of Arts and Sciences. 

    Kamran Honarnejad

    ​Group Leader for High-Throughput Drug and Target Discovery

    Fraunhofer ITEM

    Group Leader for High-Throughput Drug and Target Discovery at Fraunhofer ITEM, KCDC co-chair and NPA judge panel member at SLAS

    Anna Greka, MD, Ph.D.

    BWH/Harvard/Broad

    Anna Greka is a physician-scientist leading the translation of scientific discoveries from the laboratory to clinical trials. She is an Associate Professor at Harvard Medical School (HMS); an Associate Physician in the Renal Division in the Department of Medicine at Brigham and Women’s Hospital (BWH); and the founding director of Kidney-NExT, a Center for Kidney Disease and Novel Experimental Therapeutics at BWH. Dr. Greka is also an Institute Member of the Broad Institute of MIT and Harvard, where she directs the institute’s Kidney Disease Initiative (KDI) and the ion channel therapeutics interest group (CHAnnel Therapeutics, CHArT).

    Jackie Hunter, Ph.D.

    Board Director

    BenevolentAI

    Jackie Hunter is currently a Board Director of BenevolentAI as well as CE of Clinical and Strategic Partnerships. BenevolentAI uses AI to augment the research capabilities of drug scientists, radically changing the way R&D is done. She has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She has also served on numerous academic, industry and government Boards and panels in both Europe and America e.g. in the establishment of the Innovative Medicines Initiative (IMI), a 2B euro public-private partnership between the pharmaceutical industry and the European Commission and she was one of the first Board members of IMI.

    For 3 years she was the CEO of the BBSRC which was the major funder of bioscience research and its translation. In that capacity she led on developing an Equality & Diversity Strategy for all the UK Research Councils (now UKRI). She is an Honorary Professor at St George's Hospital Medical School and Imperial College, was awarded a CBE in the Queen's Birthday Honours list for Services to the Pharmaceutical Industry and was recently recognized by Forbes Magazine as one of the top 20 Women Advancing AI Research. She is passionate about diversity in all its forms!

    Leroy Cronin

    Regius Professor of Chemistry

    University of Glasgow

    Leroy (Lee) Cronin FRSE is the Regius Professor of Chemistry in Glasgow. Since the age of 9 Lee has wanted to explore chemistry using electronics to control matter, understand the origin of life, and generally confuse people with ideas that may or may not make sense one day. He strives to use his imagination to create new ideas that might tell us something about the universe. His research has four main aims 1) the construction of an artificial life form / work out how inorganic chemistry transitioned to biology / searching for new life forms; 2) the digitization of chemistry; and 3) the use of artificial intelligence in chemistry including the construction of ‘wet’ chemical computers; 4) The exploration of complexity and information in chemistry. Lee does not like hierarchy but likes organisation and well-defined actions.Nothing is impossible until it is tried. See www.croninlab.com

    Jimmy Wu

    Translational Research Institute for Space Health

    Jimmy Wu is the Senior Biomedical Engineer at the Translational Research Institute for Space Health (TRISH). His role is to facilitate delivery of project deliverables to TRISH and NASA. Previously, Jimmy worked at NASA Johnson Space Center for fourteen years providing engineering, integration, operations, research and development, information technology, and project management support to projects addressing human health and performance during space flight missions.

    Rekha Hemrajani

    Adverum

    Rekha Hemrajani is an experienced strategic leader helping biotech companies with corporate strategy and corporate finance, as well as building product pipelines through corporate development (both buy side and sell side). She is a strong team builder with extensive senior management experience within public and private biotechnology and pharma companies, investment funds and bulge bracket investment banks.

    Recently, as CFO & COO of Arcus Biosciences, a publicly-traded clinical stage company focused on developing cancer therapeutics, Rekha led finance, investor relations, corporate communications, business and corporate development, strategic planning and human resources. Previously as COO of FLX Bio, a venture funded immune-oncology company, Rekha was responsible for corporate strategy, corporate development, finance, investor & public relations, corporate communications, strategic marketing and G&A operations including legal, facilities and IT. Following the spin-off of FLX from its predecessor company, she has helped FLX restructure and rebuild the product portfolio, grow the company from ~35 to ~65 employees and lead the company through multiple rounds of financing raising > $140 M in private capital.

    Previously, in various roles, Rekha has helped companies prepare for and execute IPOs, corporate communication and investor relations strategies, in- and out-licensing of products, mergers & acquisitions and portfolio prioritization. Rekha has experience in the therapeutic areas of oncology, immunology, metabolic diseases as well as endocrinology.

    Rekha holds an MBA from the Kellogg School of Management at Northwestern University and a Bachelor of Science from University of Michigan. She serves on the Board of Directors of Hemmo Pharmaceuticals, Pvt Ltd, Mumbai, India, on the Investment Advisory Board of University of Michigan’s Monroe-Brown Seed Fund in Ann Arbor, Michigan as well as on the Board of Regents of Junipero Serra High School in San Mateo, California.

    Elizabeth Iorns, Ph.D.

    Founder & CEO

    Science Exchange

    Dr. Elizabeth Iorns is the Founder & CEO of Science Exchange, the Co-Director of the Reproducibility Initiative, and is a part-time partner at Y Combinator. Elizabeth has a Ph.D. in Cancer Biology from the Institute of Cancer Research (UK), and before starting Science Exchange in 2011 was an Assistant Professor at the University of Miami (where she remains an Adjunct Professor). Elizabeth has received a range of honors and recognition, including the Kauffman Foundation Emerging Entrepreneur Award, one of Nature Magazine’s ‘Ten People Who Mattered’, and one of WIRED’s '50 Women Who Are Changing The World'. Elizabeth is focused on the development of innovative models to promote the quality and efficiency of scientific research.

    Phyllis Whiteley, PhD.

    Wildcat Venture Partners

    Phyllis Whiteley, PhD., is a Venture Capitalist and a Life Sciences consultant. She is currently a Venture Partner with Wildcat Venture Partners where she provides hands-on leadership in building, investing, and creating companies in the digital health space. She is also a Venture Partner with Mohr Davidow Ventures where she focused on diagnostics, life science tools, digital health, and personalized medicine including Verinata Health, acquired by Illumina (NASDAQ: ILMN). Phyllis’ career is grounded on her passion for personalized medicine, global healthcare, and transformative life science innovations. She has founded and built multiple companies in the United States and abroad. She is on the Board of Carrum Health and Balance Therapeutics.

    Her executive expertise includes strategic planning, R&D, start-ups, M&A, restructuring, and building executive teams. Prior to joining WVP and MDV, Phyllis was an EIR with 5am Ventures where she co-founded Anaphore (now Bird Rock Bio). Prior to VC, Phyllis was an Officer and SVP, Business Development, Licensing, and Alliance Management at Perlegen Sciences, Inc. Before Perlegen, she served as VP, Strategic Portfolio Management for Roche. Over her ten-year career with Roche she held various positions in Business Development based in Basel, Switzerland coupled with R&D leadership positions in the US. Phyllis also held a Senior Research Immunology role with Merck.
    Phyllis is dedicated to helping entrepreneurs address global problems. She sits on the advisory boards of UCSF Leadership Council for Global Health, University of Michigan School of Nursing Board for Science and Innovation, is a Global Social Benefits Mentor at Santa Clara University and chairs the advisory board for the University of Texas Horizon Fund. Phyllis also serves on the board of Alydia Health, a medical device company treating Post-Partum Hemorrhage.

    Phyllis holds a BA in Chemistry and Ph.D. in Pharmacology from Washington University, St. Louis, Missouri.

    Nancy Allbritton, M.D., Ph.D.

    Frank & Julie Jungers Dean of Engineering and Professor of Bioengineering

    University of Washington

    Nancy L. Allbritton is the Frank & Julie Jungers Dean of Engineering and Professor of Bioengineering at the University of Washington in Seattle (2019- current). From 2009-2019, she was the Kenan Professor of Chemistry and Biomedical Engineering and Chair of the Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill (UNC) and North Carolina State University (NC State). Her research focuses on the development of novel technologies for applications in single-cell analysis, micro-arrays and fluidics, and organ-on-chip and has resulted in over 180 full-length journal publications and patents and led to 15 commercial products. Four companies have been formed based on her research discoveries: Protein Simple (acquired by Bio-Techne in 2014), Intellego, Cell Microsystems (www.cellmicrosystems.com), and Altis Biosystems (www.altisbiosystems.com). Dr. Allbritton is a Fellow of the American Association for the Advancement of Science, the American Institute for Medical & Biological Engineering, and the National Academy of Inventors. She obtained her B.S. in physics from Louisiana State University, M.D. from Johns Hopkins University, and Ph.D. in Medical Physics/Medical Engineering from the Massachusetts Institute of Technology, with a postdoctoral fellowship at Stanford University.

    June Lee, M.D.

    Myokardia, Inc.

    June Lee, M.D., has significant experience leading early clinical development programs and is also a recognized leader in academic translational research. Dr. Lee is an adjunct professor at the University of California, San Francisco (UCSF) School of Medicine, where she formerly served as Director of Translational Research and Director of Catalyst Program which is an internal accelerator at UCSF for early stages technologies in therapeutics, devices, diagnostics, and digital health. A key focus of Dr. Lee’s work was identifying the most compelling discovery research and enabling and supporting its commercialization. Previously, she worked in early clinical development in cardiovascular, metabolism, respiratory, and infectious diseases at Genentech. Dr. Lee serves as chair of the Board of Directors for the Council of Korean Americans. She is also a member of the Translational Research Advisory Council of the MOGAM Research Institute, and the MTRAC for Life Sciences Innovation Hub Therapeutic/Diagnostic Oversight Committee, a unit associated with The University of Michigan Medical School.

    Dr. Lee completed her undergraduate work in chemistry at the Johns Hopkins University, earned her M.D. degree at the School of Medicine at University of California, Davis, and her clinical training in internal medicine and pulmonary/critical care and UCLA and UCSF.

    Raphael Werding

    Global Product Manager for Genomic Services

    QIAGEN GmbH

    Raphael Werding is the Global Product Manager for Genomic Services at QIAGEN. He is in charge of initiating master collaboration agreements with leading pharmaceutical and biotech companies to create Sample to Insight solutions for Precision Medicine. Each patient’s unique genomic and epigenomic characteristics are used to guide diagnostic assay development and eventually clinical decision-making for treatment. Raphael’s focus is to support customers on their journey from biomarker discovery over translational research up to clinical diagnostic assay development.

    Anne Carpenter

    Institute Scientist

    Broad Institute of Harvard and MI

    Dr. Anne Carpenter is an Institute Scientist at the Broad Institute of Harvard and MIT. Her research group develops algorithms and strategies for large-scale experiments involving images. The team’s open-source CellProfiler software is used by thousands of biologists worldwide (www.cellprofiler.org). Carpenter is a pioneer in image-based profiling, the extraction of rich, unbiased information from images for a number of important applications in drug discovery and functional genomics.

    Carpenter focused on high-throughput image analysis during her postdoctoral fellowship at the Whitehead Institute for Biomedical Research and MIT’s CSAIL (Computer Sciences/Artificial Intelligence Laboratory). Her PhD is in cell biology from the University of Illinois, Urbana-Champaign. Carpenter has been named an NSF CAREER awardee, an NIH MIRA awardee, a Massachusetts Academy of Sciences fellow (its youngest at the time), a Genome Technology “Rising Young Investigator”, and is listed in Deep Knowledge Analytics’ top-100 AI Leaders in Drug Discovery and Advanced Healthcare.

    Yilian Wang

    UCLA Bioengineering

    Jonathan Hull, Ph.D.

    Vice President

    Bioelectronica

    Per Setterberg

    CEO

    Iscaffpharma

    Sebastian Metz, Ph.D.

    CEO

    Byonoy GmbH

    Hugo Sinha, MASc

    CEO

    DropGenie

    Lowry Curley, Ph.D.

    CEO

    AxoSim Inc.

    Patrick Walsh, M.S.

    CEO

    Anatomi Corp.

    Tei Newman-Lehman

    CEO

    DeepDiveBio, Inc.

    Michele Zagnoni, Ph.D.

    Chief Scientific Officer

    ScreenIn3D

    Mark Harfouche, Ph.D.

    Co-founder

    Ramona Optics, Inc.

    Dan Close, Ph.D.

    490 BioTech, Inc.

    Dan Close obtained his doctorate in 2011 through the development of a synthetic luciferase-based imaging technology that enabled autonomous bioluminescent production in human cells. Following Dr. Close’s development of this technology, it was successfully commercialized by 490 BioTech, Inc. Upon completion of his graduate work, Dr. Close took a position as a Postdoctoral Research Associate in the Joint Institute for Biological Sciences, a partnership between The University of Tennessee and Oak Ridge National Laboratory. In 2012 Dr. Close was selected as a Eugene P. Wigner Fellow by the Department of Energy’s Oak Ridge National Laboratory in Oak Ridge, Tennessee. Following the completion of his Eugene P. Wigner Fellowship appointment, Dr. Close continued his work as a Research Staff Scientist in the laboratory’s Biosciences Division. In 2018, Dr. Close become the chief scientific officer of 490 BioTech, the company founded on the autobioluminescent technology he developed during his graduate work.

    Paul Hung, Ph.D.

    Founder

    COMBiNATi Inc

    Paul Hung has 11 years of experience developing life science research tools using microfluidic technology. After receiving his PhD from UC Berkeley in 2005, he has successfully grown CellASIC Corporation, which he co-founded in 2006, to self-sufficiency with the commercialization of the ONIX live cell imaging platform, and sold to MillporeSigma (then EMD Millipore) in 2012. After the acquisition, he worked as a senior R&D manager to gain more knowledge in systematic product development in a large corporate. He founded COMBiNATi in 2016 to continue driving the vision of disrupting the life science industry with microfluidic technology, one consumable at a time.

    Karen Wu, Ph.D.

    Co-Founder and the President

    Lucerna, Inc

    Dr. Karen Wu is a Co-Founder and the President at Lucerna. She has over 20 years of experience in RNA technology and has launched several research tool products into the life science reagents market.

    Arne Vandenbroucke, Ph.D.

    Sr. Automation Engineer

    Synthace Ltd

    Akwasi Apori, Ph.D.

    CEO

    Correlia Biosystems

  • Contains 1 Component(s)

    Ngiam Kee Yuan discusses the use of data to develop virtual models that allow earlier prediction of disease and use of natural-language data to drive medical conclusions.

    Join the SLAS Scientific Director, and the AI in Process Automation Symposium Program Committee members as they talk with Dr. Ngiam Kee Yuan, the Group Chief Technology Officer of the National University Health System (NUHS) Singapore, about his group's efforts to use data to develop virtual models that allow earlier prediction of disease and use of natural-language data to drive medical conclusions.

    Ngiam Kee Yuan, MBBS, MRCS, Mmed, FRCS

    Group Chief Technology Officer

    National University Health System (NUHS) Singapore

    Dr. Ngiam Kee Yuan is the Group Chief Technology Officer of the National University Health System (NUHS) Singapore overseeing technology deployment in Western Healthcare Cluster of Singapore. The cluster incorporates one large academic medical center, three national centers of excellence, two acute hospitals, one community hospital, six polyclinics and four schools under the National University of Singapore. In this role, he assists the Chief Executive to implement new technologies throughout NUHS and serves as the Chief Advisor to the Center for Innovation in Healthcare in NUHS. Dr. Ngiam is concurrently the Deputy Chief Medical Informatics Officer at the National University Hospital of Singapore with a special focus on artificial intelligence research and implementation in healthcare. He has certification training by the American Medical Informatics Association and has published in computing and medical journals on topics related to healthcare AI applications and technology.

    Dr. Ngiam is a Consultant Thyroid and Endocrine Surgeon at the Department of Surgery, National University Hospital, Singapore specializing in thyroid oncology and minimally invasive endoscopic and robotic thyroid surgery. He obtained his undergraduate degree from the Royal Free and University College Medical School, London (now University College London) followed by Advanced Surgical Training in General Surgery and was awarded a fellowship from the Royal College of Surgeons of Edinburgh upon completion of his training. He is an accredited general surgery specialist by the Specialist Accreditation Board, Singapore and received the Higher Manpower Development Award to complete a fellowship in Metabolic Surgery in Taiwan. He received further training in robotic thyroid surgery at the Seoul National University Hospital, South Korea.

    In his capacity as Assistant Professor, Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Dr. Ngiam engages in research into endocrine and metabolic surgery as well as artificial intelligence applications in healthcare. He promotes interdisciplinary collaboration throughout the NUS campus, particularly between the schools of medicine, engineering and computer science for various healthcare applications. He was awarded the ExxonMobil-NUS Research Fellowship for Clinicians and numerous teaching awards for his work in research and education.

    Dr. Ngiam is also an active volunteer and is the Mission Chief for a number of ground-up surgical missions to regional countries such as Myanmar and Indonesia; under the auspices of the Surgical Outreach to Underserved Localities (SOUL) program with the NUH Department of Surgery.

  • Contains 4 Component(s)

    Spark your passion and ignite your career with these Career Connection discussions from SLAS2021 Digital.

    READY TO TUNE UP YOUR CAREER? You're already in the right place and ahead of the curve. You're learning new and critical information with SLAS2021 Digital. Time to put that new info into practice- spark your passion and ignite your career.

    Ashley Wallace, Ph.D.

    University of Pennsylvania

    Chartanay Bonner, Ph.D.

    Western Michigan University

    Trishelle Copeland-Johnson, Ph.D.

    Iowa State University

    Victoria S. Parker, Ph.D.

    Massachusetts General Hospital/Harvard Medical School

    Shastine Keeney

    Principal Laboratory Automation Engineer

    Zevon Automation Consulting Services

    Joanne Kamens, Ph.D.

    Executive Director

    Addgene